FDA approved drugs:
(show all 27)
| # |
|
Drug Name |
Active Ingredient(s) 18
|
Company |
Approval Date |
| 1 |
|
Adcetris
18
49
|
BRENTUXIMAB VEDOTIN |
Seattle Genetics |
August 2011 |
Disease/s that Drug Treats:Hodgkin lymphoma and anaplastic large cell lymphoma
Indications and Usage:
18
ADCETRIS is a CD30-directed antibody-drug conjugate indicated fortreatment of patients with: Hodgkin lymphoma after failure of autologous stem cell transplant(ASCT) or after failure of at least two prior multi-agent chemotherapyregimens in patients who are not ASCT candidates (1.1). Systemic anaplastic large cell lymphoma after failure of at least oneprior multi-agent chemotherapy regimen (1.2).Accelerated approval was granted for the above indications based onoverall response rate. An improvement in patient-reported outcomes orsurvival has not been established. Continued approval for these indicationsmay be contingent upon verification and description of clinical benefit inconfirmatory trials.
DrugBank Targets:
16
Tumor necrosis factor receptor superfamily member 8
Mechanism of Action:
18
Target: microtubule
Action: disruptor
FDA: Brentuximab vedotin is an ADC. The antibody is a chimeric IgG1 directed against CD30. Thesmall molecule, MMAE, is a microtubule disrupting agent. MMAE is covalently attached to theantibody via a linker. Nonclinical data suggest that the anticancer activity of ADCETRIS is dueto the binding of the ADC to CD30-expressing cells, followed by internalization of theADC-CD30 complex, and the release of MMAE via proteolytic cleavage. Binding of MMAE totubulin disrupts the microtubule network within the cell, subsequently inducing cell cycle arrestand apoptotic death of the cells.
|
| 2 |
|
Arranon
18
49
|
NELARABINE |
GlaxoSmithKline |
October 2005 |
Disease/s that Drug Treats:Lymphoblastic Leukemia
Indications and Usage:
18
ARRANON is a nucleoside metabolic inhibitor indicated for the treatment ofpatients with T-cell acute lymphoblastic leukemia and T-cell lymphoblasticlymphoma whose disease has not responded to or has relapsed followingtreatment with at least two chemotherapy regimens. This use is based on theinduction of complete responses. Randomized trials demonstrating increasedsurvival or other clinical benefit have not been conducted. (1)
Mechanism of Action:
18
Target: DNA synthesis
Action: disruptor --> apoptosis
FDA: Nelarabine is a pro-drug of the deoxyguanosine analogue 9-β-D-arabinofuranosylguanine266 (ara-G), a nucleoside metabolic inhibitor. Nelarabine is demethylated by adenosine deaminase267 (ADA) to ara-G, mono-phosphorylated by deoxyguanosine kinase and deoxycytidine kinase, and268 subsequently converted to the active 5â-triphosphate, ara-GTP. Accumulation of ara-GTP in269 leukemic blasts allows for incorporation into deoxyribonucleic acid (DNA), leading to inhibition270 of DNA synthesis and cell death. Other mechanisms may contribute to the cytotoxic and271 systemic toxicity of nelarabine.
|
| 3 |
|
Arzerra
18
49
|
OFATUMUMAB |
GlaxoSmithKline |
October 2009 |
Disease/s that Drug Treats:chronic lymphocytic leukemia
Indications and Usage:
18
ARZERRA (ofatumumab) is a CD20-directed cytolytic monoclonal antibodyindicated: in combination with chlorambucil, for the treatment of previouslyuntreated patients with chronic lymphocytic leukemia (CLL) for whomfludarabine-based therapy is considered inappropriate. (1.1) for the treatment of patients with CLL refractory to fludarabine andalemtuzumab. (1.2)
DrugBank Targets:
16
no entry
Mechanism of Action:
18
Target: B-cell
Action: promotes lysis
FDA: Ofatumumab binds specifically to both the small and large extracellular loops of the CD20402 molecule. The CD20 molecule is expressed on normal B lymphocytes (pre-B- to mature403 B-lymphocyte) and on B-cell CLL. The CD20 molecule is not shed from the cell surface and is404 not internalized following antibody binding.405406 The Fab domain of ofatumumab binds to the CD20 molecule and the Fc domain mediates407 immune effector functions to result in B-cell lysis in vitro. Data suggest that possible408 mechanisms of cell lysis include complement-dependent cytotoxicity and antibody-dependent,409 cell-mediated cytotoxicity.
|
| 4 |
|
Beleodaq
18
49
|
BELINOSTAT |
Spectrum Pharmaceuticals |
July 2014 |
Disease/s that Drug Treats:relapsed or refractory peripheral T-cell lymphoma
Indications and Usage:
18
Beleodaq is a histone deacetylase inhibitor indicated for the treatment ofpatients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Thisindication is approved under accelerated approval based on tumor responserate and duration of response. An improvement in survival or disease-relatedsymptoms has not been established. Continued approval for this indicationmay be contingent upon verification and description of clinical benefit in theconfirmatory trial. (1)
DrugBank Targets:
16
no entry
Mechanism of Action:
18
Target: histone deacetylase (HDAC)
Action: inhibitor
FDA: Beleodaq is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from thelysine residues of histones and some non-histone proteins. In vitro, belinostat caused the accumulation ofacetylated histones and other proteins, inducing cell cycle arrest and/or apoptosis of some transformed cells.Belinostat shows preferential cytotoxicity towards tumor cells compared to normal cells. Belinostat inhibitedthe enzymatic activity of histone deacetylases at nanomolar concentrations (<250 nM).
|
| 5 |
|
Bexxar
18
49
|
TOSITUMOMAB; IODINE I 131 TOSITUMOMAB |
Corixa |
June 2003 |
Disease/s that Drug Treats:Non-Hodgkin's Lymphoma
Indications and Usage:
18
BEXXAR (tositumomab and Iodine I 131 tositumomab) is a CD20-directedradiotherapeutic antibody indicated for the treatment of patients with CD20-positive, relapsed or refractory, low-grade, follicular, or transformed nonHodgkin'slymphoma who have progressed during or after rituximab therapy,including patients with rituximab-refractory non-Hodgkin's lymphoma. (1.1)Determination of the effectiveness of the BEXXAR therapeutic regimen isbased on overall response rates in patients whose disease is refractory tochemotherapy and rituximab. The effects of the BEXXAR therapeuticregimen on survival are not known. (1.1)Important Limitation of Use BEXXAR therapeutic regimen is only indicated for a single course oftreatment and is not indicated for a first-line treatment. (1.2)
DrugBank Targets:
16
1. B-lymphocyte antigen CD20;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10.Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:
18
Target: CD20
Action: cytotoxic antibody
FDA: Tositumomab binds specifically to an epitope within the extracellular domain of the586 CD20 molecule. The CD20 molecule is expressed on normal B lymphocytes (pre-B lymphocytes587 to mature B lymphocytes) and on B-cell non-Hodgkin's lymphomas. The CD20 molecule is not588 shed from the cell surface and is not internalized following antibody binding. The BEXXAR589 therapeutic regimen induces cell death by emitting ionizing radiation to CD20-expressing590 lymphocytes or neighboring cells. In addition to cell death mediated by the radioisotope, other591 possible mechanisms of action include antibody-dependent cellular cytotoxicity, complement-592 dependent cytotoxicity, and CD20-mediated apoptosis.
|
| 6 |
|
Busulfex
18
49
|
BUSULFAN |
Orphan Medical |
February 1999 |
Disease/s that Drug Treats:leukemia
Indications and Usage:
18
BUSULFEX is an alkylating drug indicated for: Use in combination with cyclophosphamide as a conditioning regimenprior to allogeneic hematopoietic progenitor cell transplantation forchronic myelogenous leukemia (CML) (1)
Mechanism of Action:
18
Target: DNA
Action: alkylyzer
FDA: Busulfan is a bifunctional alkylating agent in which two labile methanesulfonate groups are attached to opposite ends of afour-carbon alkyl chain. In aqueous media, busulfan hydrolyzes to release the methanesulfonate groups. This producesreactive carbonium ions that can alkylate DNA. DNA damage is thought to be responsible for much of the cytotoxicity ofbusulfan.
|
| 7 |
|
Elitek
18
49
|
RASBURICASE |
sanofi-aventis |
October 2009 |
Disease/s that Drug Treats:management of plasma uric acid levels in adults with malignancies
Indications and Usage:
18
Elitek is a recombinant urate-oxidase indicated for initial management ofplasma uric acid levels in pediatric and adult patients with leukemia,lymphoma, and solid tumor malignancies who are receiving anti-cancertherapy expected to result in tumor lysis and subsequent elevation of plasmauric acid (1).Limitation of use: Elitek is indicated only for a single course of treatment (1).
DrugBank Targets:
16
1. Uric acid
Mechanism of Action:
18
Target: uric acid
Action: converter to alantoin
FDA: In humans, uric acid is the final step in the catabolic pathway of purines. Rasburicase catalyzesenzymatic oxidation of poorly soluble uric acid into an inactive and more soluble metabolite(allantoin).
|
| 8 |
|
Elliotts B Solution
18
|
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE |
Orphan Medical |
October 1996 |
FDA Label: Elliotts B Solution
Disease/s that Drug Treats:meningeal leukemia or lymphocytic lymphoma
Indications and Usage:
18
DrugBank Targets:
-
Mechanism of Action:
18
Target: cerebrospinal fluid
Action: comparable in pH, electrolyte composition, glucose content, and osmolarity
FDA: -
|
| 9 |
|
Folotyn
18
49
|
PRALATREXATE |
Allos Therapeutics |
September 2009 |
Disease/s that Drug Treats:peripheral T-cell lymphoma
Indications and Usage:
18
FOLOTYN is a folate analog metabolic inhibitor indicated for the treatment ofpatients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Thisindication is based on overall response rate. Clinical benefit such asimprovement in progression-free survival or overall survival has not beendemonstrated. (1)
DrugBank Targets:
16
1. Dihydrofolate reductase;2. Thymidylate synthase
Mechanism of Action:
18
Target: dihydrofolate reductase
Action: inhibitor
FDA: Pralatrexate is a folate analog metabolic inhibitor that competitively inhibits dihydrofolate reductase. It is also acompetitive inhibitor for polyglutamylation by the enzyme folylpolyglutamyl synthetase. This inhibition resultsin the depletion of thymidine and other biological molecules the synthesis of which depends on single carbontransfer.
|
| 10 |
|
Imbruvica
18
49
|
IBRUTINIB |
Pharmacyclics |
November of 2013/February 2014 |
Disease/s that Drug Treats:mantle cell lymphoma/chronic lymphocytic leukemia
Indications and Usage:
18
IMBRUVICA is a kinase inhibitor indicated for the treatment of patients with: Mantle cell lymphoma (MCL) who have received at least one priortherapy (1.1).Accelerated approval was granted for this indication based on overallresponse rate. Continued approval for this indication may be contingentupon verification of clinical benefit in confirmatory trials. Chronic lymphocytic leukemia (CLL) who have received at least oneprior therapy (1.2). Chronic lymphocytic leukemia with 17p deletion (1.3). Waldenströmâs macroglobulinemia (WM) (1.4).
DrugBank Targets:
16
1. Tyrosine-protein kinase BTK
Mechanism of Action:
18
Target: Bruton's tyrosine kinase (Btk)
Action: selective inhibitor
FDA: Ibrutinib is a small-molecule inhibitor of BTK. Ibrutinib forms a covalent bond with a cysteineresidue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is asignaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTKâsrole in signaling through the B-cell surface receptors results in activation of pathways necessaryfor B-cell trafficking, chemotaxis, and adhesion. Nonclinical studies show that ibrutinib inhibitsmalignant B-cell proliferation and survival in vivo as well as cell migration and substrateadhesion in vitro.
|
| 11 |
|
Intron A
18
49
|
INTERFERON ALFA-2B |
Schering-Plough |
December 1997/ December 1995/ March 1997 |
Disease/s that Drug Treats:non-Hodgkin's lymphoma/ malignant melanoma / Hepatitis C
Indications and Usage:
18
Hairy Cell Leukemia INTRON® A is indicated for the treatment of patients 18 years ofage or older with hairy cell leukemia.Malignant Melanoma INTRON A is indicated as adjuvant to surgical treatment inpatients 18 years of age or older with malignant melanoma who are free of disease butat high risk for systemic recurrence, within 56 days of surgery.Follicular Lymphoma INTRON A is indicated for the initial treatment of clinicallyaggressive (see Clinical Pharmacology) follicular Non-Hodgkinâs Lymphoma inconjunction with anthracycline-containing combination chemotherapy in patients 18years of age or older. Efficacy of INTRON A therapy in patients with low-grade, lowtumorburden follicular Non-Hodgkinâs Lymphoma has not been demonstrated.Condylomata Acuminata INTRON A is indicated for intralesional treatment of selectedpatients 18 years of age or older with condylomata acuminata involving externalsurfaces of the genital and perianal areas (see DOSAGE AND ADMINISTRATION).The use of this product in adolescents has not been studied.AIDS-Related Kaposi's Sarcoma INTRON A is indicated for the treatment of selectedpatients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. The likelihoodof response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immunesystem as indicated by total CD4 count.Chronic Hepatitis C INTRON A is indicated for the treatment of chronic hepatitis C inpatients 18 years of age or older with compensated liver disease who have a history ofblood or blood-product exposure and/or are HCV antibody positive. Studies in thesepatients demonstrated that INTRON A therapy can produce clinically meaningful effectson this disease, manifested by normalization of serum alanine aminotransferase (ALT)and reduction in liver necrosis and degeneration.A liver biopsy should be performed to establish the diagnosis of chronic hepatitis.Patients should be tested for the presence of antibody to HCV. Patients with othercauses of chronic hepatitis, including autoimmune hepatitis, should be excluded. Priorto initiation of INTRON A therapy, the physician should establish that the patient hascompensated liver disease. The following patient entrance criteria for compensated liverdisease were used in the clinical studies and should be considered before INTRON Atreatment of patients with chronic hepatitis C: No history of hepatic encephalopathy, variceal bleeding, ascites, or otherclinical signs of decompensation Bilirubin Less than or equal to 2 mg/dL Albumin Stable and within normal limits Prothrombin Time Less than 3 seconds prolonged WBC Greater than or equal to 3000/mm3 Platelets Greater than or equal to 70,000/mm3Serum creatinine should be normal or near normal.Prior to initiation of INTRON A therapy, CBC and platelet counts should beevaluated in order to establish baselines for monitoring potential toxicity. These testsshould be repeated at Weeks 1 and 2 following initiation of INTRON A therapy, andmonthly thereafter. Serum ALT should be evaluated at approximately 3-month intervalsto assess response to treatment (see DOSAGE AND ADMINISTRATION).Patients with preexisting thyroid abnormalities may be treated if thyroidstimulatinghormone (TSH) levels can be maintained in the normal range by medication.TSH levels must be within normal limits upon initiation of INTRON A treatment and TSHtesting should be repeated at 3 and 6 months (see PRECAUTIONS, LaboratoryTests).INTRON A in combination with REBETOL® is indicated for the treatment ofchronic hepatitis C in patients 3 years of age and older with compensated liver diseasepreviously untreated with alpha interferon therapy and in patients 18 years of age andolder who have relapsed following alpha interferon therapy. See REBETOL prescribinginformation for additional information. Chronic Hepatitis B INTRON A is indicated for the treatment of chronic hepatitis B inpatients 1 year of age or older with compensated liver disease. Patients who have beenserum HBsAg positive for at least 6 months and have evidence of HBV replication(serum HBeAg positive) with elevated serum ALT are candidates for treatment. Studiesin these patients demonstrated that INTRON A therapy can produce virologic remissionof this disease (loss of serum HBeAg) and normalization of serum aminotransferases.INTRON A therapy resulted in the loss of serum HBsAg in some responding patients.Prior to initiation of INTRON A therapy, it is recommended that a liver biopsy beperformed to establish the presence of chronic hepatitis and the extent of liver damage.The physician should establish that the patient has compensated liver disease. Thefollowing patient entrance criteria for compensated liver disease were used in theclinical studies and should be considered before INTRON A treatment of patients withchronic hepatitis B: No history of hepatic encephalopathy, variceal bleeding, ascites, or othersigns of clinical decompensation Bilirubin Normal Albumin Stable and within normal limits Prothrombin Time Adults less than 3 seconds prolongedPediatrics less than or equal to 2 seconds prolonged WBC Greater than or equal to 4000/mm3 Platelets Adults greater than or equal to 100,000/mm3Pediatrics greater than or equal to 150,000/mm3Patients with causes of chronic hepatitis other than chronic hepatitis B or chronichepatitis C should not be treated with INTRON A. CBC and platelet counts should beevaluated prior to initiation of INTRON A therapy in order to establish baselines formonitoring potential toxicity. These tests should be repeated at treatment Weeks 1, 2,4, 8, 12, and 16. Liver function tests, including serum ALT, albumin, and bilirubin,should be evaluated at treatment Weeks 1, 2, 4, 8, 12, and 16. HBeAg, HBsAg, andALT should be evaluated at the end of therapy, as well as 3- and 6-months posttherapy,since patients may become virologic responders during the 6-month periodfollowing the end of treatment. In clinical studies in adults, 39% (15/38) of respondingpatients lost HBeAg 1 to 6 months following the end of INTRON A therapy. Ofresponding patients who lost HBsAg, 58% (7/12) did so 1 to 6 months post-treatment.A transient increase in ALT greater than or equal to 2 times baseline value (flare)can occur during INTRON A therapy for chronic hepatitis B. In clinical trials in adultsand pediatrics, this flare generally occurred 8 to 12 weeks after initiation of therapy andwas more frequent in responders (adults 63%, 24/38; pediatrics 59%, 10/17) than innonresponders (adults 27%, 13/48; pediatrics 35%, 19/55). However, in adults andpediatrics, elevations in bilirubin greater than or equal to 3 mg/dL (greater than or equalto 2 times ULN) occurred infrequently (adults 2%, 2/86; pediatrics 3%, 2/72) duringtherapy. When ALT flare occurs, in general, INTRON A therapy should be continued unless signs and symptoms of liver failure are observed. During ALT flare, clinicalsymptomatology and liver function tests including ALT, prothrombin time, alkalinephosphatase, albumin, and bilirubin, should be monitored at approximately 2-weekintervals (see WARNINGS).
DrugBank Targets:
16
1. Interferon alpha/beta receptor 2;2. Interferon alpha/beta receptor 1
Mechanism of Action:
18
Target: intracellular oncogene expression, natural killer and cytotoxic T-cells, microphage, cytokine production
Action: stimulation, induction (unspecified effects on oncogene expression)
FDA: -
|
| 12 |
|
Istodax
18
49
|
ROMIDEPSIN |
Gloucester Pharmaceuticals |
November 2009 |
Disease/s that Drug Treats:cutaneous T-cell lymphoma
Indications and Usage:
18
ISTODAX is a histone deacetylase (HDAC) inhibitor indicated for: Treatment of cutaneous T-cell lymphoma (CTCL) in patients who havereceived at least one prior systemic therapy (1). Treatment of peripheral T-cell lymphoma (PTCL) in patients who havereceived at least one prior therapy (1).These indications are based on response rate. Clinical benefit such asimprovement in overall survival has not been demonstrated (1).
DrugBank Targets:
-
Mechanism of Action:
18
Target: histone deacetylase (HDAC)
Action: inhibitor
FDA: Romidepsin is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from acetylated lysine residues in histones, resulting in themodulation of gene expression. HDACs also deacetylate non-histone proteins, such as transcription factors. In vitro, romidepsin causes the accumulation of acetylatedhistones, and induces cell cycle arrest and apoptosis of some cancer cell lines with IC50 values in the nanomolar range. The mechanism of the antineoplastic effect ofromidepsin observed in nonclinical and clinical studies has not been fully characterized.
|
| 13 |
|
Kyprolis
18
49
|
CARFILZOMIB |
Onyx Pharmaceuticals |
July 2012 |
Disease/s that Drug Treats:multiple myeloma
Indications and Usage:
18
Kyprolis is a proteasome inhibitor that is indicated in combination with lenalidomide and dexamethasone for the treatment ofpatients with relapsed multiple myeloma who have received one to threeprior lines of therapy . (1, 14) as a single agent for the treatment of patients with multiple myeloma whohave received at least two prior therapies including bortezomib and animmunomodulatory agent and have demonstrated disease progression on orwithin 60 days of completion of the last therapy. Approval is based onresponse rate. Clinical benefit, such as improvement in survival orsymptoms, has not been verified. (1, 14)
DrugBank Targets:
16
1. Proteasome subunit beta type-5;2. Proteasome subunit beta type-8;3. Proteasome subunit beta type-1;4. Proteasome subunit beta type-9;5. Proteasome subunit beta type-2;6. Proteasome subunit beta type-10
Mechanism of Action:
18
Target: tetrapeptide epoxyketone proteasome
Action: inhibitor
FDA: Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds to theN-terminal threonine-containing active sites of the 20S proteasome, the proteolytic coreparticle within the 26S proteasome. Carfilzomib had antiproliferative and proapoptoticactivities in vitro in solid and hematologic tumor cells. In animals, carfilzomib inhibitedproteasome activity in blood and tissue and delayed tumor growth in models of multiplemyeloma, hematologic, and solid tumors.
|
| 14 |
|
Mozobil
18
49
|
PLERIXAFOR |
Genzyme |
December 2008 |
Disease/s that Drug Treats:non-Hodgkinâs lymphoma and multiple myeloma
Indications and Usage:
18
Mozobil, a hematopoietic stem cell mobilizer, is indicated in combinationwith granulocyte-colony stimulating factor (G-CSF) to mobilizehematopoietic stem cells (HSCs) to the peripheral blood for collection andsubsequent autologous transplantation in patients with non-Hodgkinâslymphoma and multiple myeloma. (1)
DrugBank Targets:
16
1. C-X-C chemokine receptor type 4
Mechanism of Action:
18
Target: hematopoietic stem cell/ CXCR4 chemokine receptor
Action: monilizer/ inhibitor
FDA: Plerixafor is an inhibitor of the CXCR4 chemokine receptor and blocks binding of its cognateligand, stromal cell-derived factor-1α (SDF-1α). SDF-1α and CXCR4 are recognized to play arole in the trafficking and homing of human hematopoietic stem cells (HSCs) to the marrowcompartment. Once in the marrow, stem cell CXCR4 can act to help anchor these cells to themarrow matrix, either directly via SDF-1α or through the induction of other adhesion molecules.Treatment with plerixafor resulted in leukocytosis and elevations in circulating hematopoieticprogenitor cells in mice, dogs and humans. CD34+ cells mobilized by plerixafor were capable ofengraftment with long-term repopulating capacity up to one year in canine transplantationmodels.
|
| 15 |
|
Neumega
18
|
OPRELVEKIN |
Genetics Institute |
November 1997 |
Disease/s that Drug Treats:platelet deficiency
Indications and Usage:
18
Neumega is indicated for the prevention of severe thrombocytopenia and the reduction of theneed for platelet transfusions following myelosuppressive chemotherapy in adult patients withnonmyeloid malignancies who are at high risk of severe thrombocytopenia. Efficacy wasdemonstrated in patients who had experienced severe thrombocytopenia following the previouschemotherapy cycle. Neumega is not indicated following myeloablative chemotherapy (seeWARNINGS, Increased Toxicity Following Myeloablative Therapy). The safety andeffectiveness of Neumega have not been established in pediatric patients.
DrugBank Targets:
16
1. Interleukin-11 receptor subunit alpha
Mechanism of Action:
18
Target: bone-forming and bone-resorbing cells (additionally other non-hematopoietic activities)
Action: stimulator of megakaryocytopoiesis andthrombopoiesis
FDA: The primary hematopoietic activity of Neumega is stimulation of megakaryocytopoiesis andthrombopoiesis. Neumega has shown potent thrombopoietic activity in animal models ofcompromised hematopoiesis, including moderately to severely myelosuppressed mice andnonhuman primates. In these models, Neumega improved platelet nadirs and accelerated plateletrecoveries compared to controls.Preclinical trials have shown that mature megakaryocytes which develop during in vivo treatmentwith Neumega are ultrastructurally normal. Platelets produced in response to Neumega weremorphologically and functionally normal and possessed a normal life span.IL-11 has also been shown to have non-hematopoietic activities in animals including theregulation of intestinal epithelium growth (enhanced healing of gastrointestinal lesions), theinhibition of adipogenesis, the induction of acute phase protein synthesis, inhibition of pro-inflammatory cytokine production by macrophages, and the stimulation of osteoclastogenesisand neurogenesis. Non-hematopoietic pathologic changes observed in animals include fibrosis oftendons and joint capsules, periosteal thickening, papilledema, and embryotoxicity (seePRECAUTIONS, Pediatric Use and PRECAUTIONS, Pregnancy Category C).IL-11 is produced by bone marrow stromal cells and is part of the cytokine family that shares thegp130 signal transducer. Primary osteoblasts and mature osteoclasts express mRNAs for both IL-11 receptor (IL-11R alpha) and gp130. Both bone-forming and bone-resorbing cells are potentialtargets of IL-11. (1)
|
| 16 |
|
Revlimid
18
49
|
LENALIDOMIDE |
Celgene |
June 2013 |
Disease/s that Drug Treats:mantle cell lymphoma
Indications and Usage:
18
REVLIMID is a thalidomide analogue indicated for the treatment of patientswith: Multiple myeloma (MM), in combination with dexamethasone (1.1). Transfusion-dependent anemia due to low- or intermediate-1-riskmyelodysplastic syndromes (MDS) associated with a deletion 5qabnormality with or without additional cytogenetic abnormalities (1.2). Mantle cell lymphoma (MCL) whose disease has relapsed or progressedafter two prior therapies, one of which included bortezomib (1.3).Limitations of Use: REVLIMID is not indicated and is not recommended for the treatmentof patients with chronic lymphocytic leukemia (CLL) outside ofcontrolled clinical trials (1.4).
DrugBank Targets:
16
1. Protein cereblon;2. Tumor necrosis factor ligand superfamily member 11;3. Cadherin-5;4. Prostaglandin G/H synthase 2
Mechanism of Action:
18
Target: T cells and natural killer cells/ pro-inflammatory cytokines by monocytes
Action: activator/inhibitor
FDA: Lenalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Lenalidomide inhibitsproliferation and induces apoptosis of certain hematopoietic tumor cells including multiple myeloma, mantle cell lymphoma, and del (5q)myelodysplastic syndromes in vitro. Lenalidomide causes a delay in tumor growth in some in vivo nonclinical hematopoietic tumor modelsincluding multiple myeloma. Immunomodulatory properties of lenalidomide include activation of T cells and natural killer (NK) cells, increasednumbers of NKT cells, and inhibition of pro-inflammatory cytokines (e.g., TNF-α and IL-6) by monocytes. In multiple myeloma cells, thecombination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis.
|
| 17 |
|
Rituxan
18
49
|
RITUXIMAB |
Biogen IDEC, Genentech |
November 1997 |
Disease/s that Drug Treats:non-hodgkin's lymphoma
Indications and Usage:
18
Rituxan® (rituximab) is a CD20-directed cytolytic antibody indicated for thetreatment of patients with: Non-Hodgkinâs Lymphoma (NHL) (1.1) Chronic Lymphocytic Leukemia (CLL) (1.2) Rheumatoid Arthritis (RA) in combination with methotrexate in adultpatients with moderately-to severely-active RA who have inadequateresponse to one or more TNF antagonist therapies (1.3) Granulomatosis with Polyangiitis (GPA) (Wegenerâs Granulomatosis) andMicroscopic Polyangiitis (MPA) in adult patients in combination withglucocorticoids (1.4)Limitations of Use: Rituxan is not recommended for use in patients withsevere, active infections (1.5).
DrugBank Targets:
16
1. Low affinity immunoglobulin gamma Fc region receptor III-B;2. Complement C1r subcomponent;3. Complement C1q subcomponent subunit A;4. Complement C1q subcomponent subunit B;5. Complement C1q subcomponent subunit C;6. Low affinity immunoglobulin gamma Fc region receptor III-A;7. Complement C1s subcomponent;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10. Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c;12. B-lymphocyte antigen CD20
Mechanism of Action:
18
Target: CD20 antigen expressed on the surface ofpre-B and mature B-lymphocytes
Action: mediator of B-cell lysis through different possible types of cytotoxicity
FDA: Rituximab is a monoclonal antibody that targets the CD20 antigen expressed on the surface ofpre-B and mature B-lymphocytes. Upon binding to CD20, rituximab mediates B-cell lysis. Possiblemechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependentcell mediated cytotoxicity (ADCC). The antibody induced apoptosis in the DHL 4 human B celllymphoma cell line.B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associatedchronic synovitis. In this setting, B cells may be acting at multiple sites in theautoimmune/inflammatory process, including through production of rheumatoid factor (RF) andother autoantibodies, antigen presentation, T-cell activation, and/or proinflammatory cytokineproduction.
|
| 18 |
|
Targretin
18
49
|
bexarotene |
VALEANT LUXEMBOURG |
12/29/1999 |
Disease/s that Drug Treats:cutaneous T-cell lymphoma
Indications and Usage:
18
TARGRETIN (bexarotene) is a retinoid indicated for the treatment ofcutaneous manifestations of cutaneous T-cell lymphoma in patients who arerefractory to at least one prior systemic therapy. (1)
DrugBank Targets:
16
1. Retinoic acid receptor RXR-alpha;2. Retinoic acid receptor RXR-beta;3. Retinoic acid receptor RXR-gamma
Mechanism of Action:
18
Target: retinoid X receptor subtypes (RXRalpha, RXRbeta, RXRgama)
Action: activator
FDA: Bexarotene selectively binds and activates retinoid X receptor subtypes (RXRï¡, RXRï¢, RXRï§).RXRs can form heterodimers with various receptor partners such as retinoic acid receptors (RARs),vitamin D receptor, thyroid receptor, and peroxisome proliferator activator receptors (PPARs). Onceactivated, these receptors function as transcription factors that regulate the expression of genes thatcontrol cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of sometumor cell lines of hematopoietic and squamous cell origin. It also induces tumor regression in vivoin some animal models. The exact mechanism of action of bexarotene in the treatment of cutaneousT-cell lymphoma (CTCL) is unknown.
|
| 19 |
|
Treanda
18
49
|
BENDAMUSTINE HYDROCHLORIDE |
Cephalon |
October 2008 |
Disease/s that Drug Treats:Chronic lymphocytic leukemia and B-cell non-Hodgkinâs lymphoma
Indications and Usage:
18
TREANDA is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first linetherapies other than chlorambucil has not been established. (1.1) Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed duringor within six months of treatment with rituximab or a rituximab-containingregimen. (1.2)
DrugBank Targets:
-
Mechanism of Action:
18
Target: -
Action: -
FDA: Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring.Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electronrichnucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to celldeath via several pathways. Bendamustine is active against both quiescent and dividing cells. The exact mechanism ofaction of bendamustine remains unknown.
|
| 20 |
|
UVADEX
18
|
METHOXSALEN |
Therakos |
February 1999 |
Disease/s that Drug Treats:skin manifestations of cutaneous T-cell lymphoma (CTCL)
Indications and Usage:
18
UVADEX⢠(methoxsalen) Sterile Solution is indicated for extracorporeal administration withthe UVAR⢠XTS⢠or THERAKOS⢠CELLEX⢠Photopheresis System in the palliativetreatment of the skin manifestations of Cutaneous T-Cell Lymphoma (CTCL) that isunresponsive to other forms of treatment.
DrugBank Targets:
16
1. DNA
Mechanism of Action:
18
Target: DNA
Action: inhibitor of DNA synthesis, cell division, and epidermal turnover
FDA: The exact mechanism of action of methoxsalen is not known. The best-known biochemicalreaction of methoxsalen is with DNA. Methoxsalen, upon photoactivation, conjugates and formscovalent bonds with DNA which leads to the formation of both monofunctional (addition to asingle strand of DNA) and bifunctional adducts (crosslinking of psoralen to both strands ofDNA). Reactions with proteins have also been described. The formation of photoadducts resultsin inhibition of DNA synthesis, cell division and epidermal turnover.For the palliative treatment of Cutaneous T-Cell Lymphoma, Photopheresis consists of removinga portion of the patient's blood and separating the red blood cells from the white cell layer (buffycoat) by centrifugation. The red cells are returned to the patient and the UVADEX⢠SterileSolution is then injected into the instrument and mixed with the buffy coat. The instrument thenirradiates this drug-cell mixture with ultraviolet light (UVA light, 320-400 nm) and returns thetreated cells to the patient. See the appropriate Operator's Manual for details of this process.Although extracorporeal phototherapy exposes less than 10% of the total body burden ofmalignant cells to methoxsalen plus light, some patients achieve a complete response. Animalstudies suggest that the photopheresis may activate an immune-mediated response against themalignant T-cells.Use of the UVAR⢠and UVAR⢠XTS⢠Systems after oral administration of methoxsalenwere previously approved for the treatment of Cutaneous T-Cell Lymphoma. Interpatientvariability in peak plasma concentration after an oral dose of methoxsalen ranges from 6 to 15fold. UVADEX⢠is injected directly into the separated buffy coat in the instrument in anattempt to diminish this interpatient variability and to improve the exposure of the cells to thedrug.Methoxsalen is reversibly bound to serum albumin and is also preferentially taken up byepidermal cells. Methoxsalen is rapidly metabolized in humans, with approximately 95% of thedrug excreted as metabolites in the urine within 24 hours.Systemic administration of methoxsalen followed by UVA exposure leads to cell injury. Themost obvious manifestation of this injury after skin exposure is delayed erythema, which maynot begin for several hours and peaks at 48-72 hours. The inflammation is followed over severaldays to weeks, by repair which is manifested by increased melanization of the epidermis andthickening of the stratum corneum.The total dose of methoxsalen delivered in UVADEX⢠is substantially lower (approximately200 times) than that used with oral administration. More than 80% of blood samples collected30 minutes after reinfusion of the photoactivated buffy coat had methoxsalen levels belowdetection limits of the assay (<10 ng/ml), and the mean plasma methoxsalen concentration wasapproximately 25 ng/ml.
|
| 21 |
|
Valchlor
18
|
MECHLORETHAMINE HYDROCHLORIDE |
Ceptaris Therapeutics |
August 2013 |
Disease/s that Drug Treats:Stage IA/IB mycosisfungoides-type cutaneous T-cell lymphoma
Indications and Usage:
18
VALCHLOR is an alkylating drug indicated for the topical treatmentof Stage IA and IB mycosis fungoidesâtype cutaneous Tâcelllymphoma in patients who have received prior skinâdirected therapy(1). Â
DrugBank Targets:
16
1. DNA
Mechanism of Action:
18
Target: rapidly-proliferating cells
Action: inhibitor
FDA: Mechlorethamine, also known as nitrogen mustard, is an alkylating agent which inhibits rapidly proliferating cells.
|
| 22 |
|
Velcade
18
49
|
BORTEZOMIB |
Millennium Pharmaceuticals |
May 2003 |
Disease/s that Drug Treats:Multiple Myeloma
Indications and Usage:
18
VELCADE is a proteasome inhibitor indicated for: treatment of patients with multiple myeloma (1.1) treatment of patients with mantle cell lymphoma (1.2)
DrugBank Targets:
16
1. 26S proteasome non-ATPase regulatory subunit 2;2. 26S proteasome non-ATPase regulatory subunit 1;3. Proteasome subunit beta type-1;4. Proteasome subunit beta type-5;5. Proteasome subunit beta type-2
Mechanism of Action:
18
Target: 26S proteasome
Action: reversible inhibitor of chymotrypsin-like activity
FDA: Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammaliancells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitinproteasomepathway plays an essential role in regulating the intracellular concentration of specific proteins,thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targetedproteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostaticmechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety ofcancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models,including multiple myeloma.
|
| 23 |
|
Xalkori
18
49
|
CRIZOTINIB |
Pfizer |
August of 2011 |
Disease/s that Drug Treats:ALK+ non-small cell lung cancer
Indications and Usage:
18
XALKORI is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplasticlymphoma kinase (ALK)-positive as detected by an FDA-approved test. (1), XALKORI is a kinase inhibitor indicated for the treatment of patients with: * metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (1.1) * metastatic NSCLC whose tumors are ROS1-positive. (1.2)
DrugBank Targets:
16
1. ALK tyrosine kinase receptor;2. Hepatocyte growth factor receptor, ALK tyrosine kinase receptor|Hepatocyte growth factor receptor
Mechanism of Action:
18
Target: receptor tyrosine kinases, receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and Recepteur dâOrigine Nantais (RON)
Action: inhibitor
FDA: Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor(HGFR, c-Met), ROS1 (c-ros), and Recepteur dâOrigine Nantais (RON). Translocations can affect the ALKgene resulting in the expression of oncogenic fusion proteins. The formation of ALK fusion proteins results inactivation and dysregulation of the geneâs expression and signaling which can contribute to increased cellproliferation and survival in tumors expressing these proteins. Crizotinib demonstrated concentration-dependentinhibition of ALK, ROS1, and c-Met phosphorylation in cell-based assays using tumor cell lines anddemonstrated antitumor activity in mice bearing tumor xenografts that expressed EML4- or NPM-ALK fusionproteins or c-Met. , Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), ROS1 (c-ros), and Recepteur dâOrigine Nantais (RON). Translocations can affect the ALK gene resulting in the expression of oncogenic fusion proteins. The formation of ALK fusion proteins results in activation and dysregulation of the geneâs expression and signaling which can contribute to increased cell proliferation and survival in tumors expressing these proteins. Crizotinib demonstrated concentration-dependent inhibition of ALK, ROS1, and c-Met phosphorylation in cell-based assays using tumor cell lines and demonstrated antitumor activity in mice bearing tumor xenografts that expressed echinoderm microtubule-associated protein-like 4 (EML4)- or nucleophosmin (NPM)-ALK fusion proteins or c-Met.
|
| 24 |
|
Zevalin
18
49
|
IBRITUMOMAB TIUXETAN |
Biogen IDEC |
February 2002 |
Disease/s that Drug Treats:Non-Hodgkin's lymphoma
Indications and Usage:
18
Zevalin is a CD20-directed radiotherapeutic antibody administered as part ofthe Zevalin therapeutic regimen indicated for the treatment of patients with: relapsed or refractory, low-grade or follicular B-cell non-Hodgkin'slymphoma (NHL) (1.1). previously untreated follicular NHL who achieve a partial or completeresponse to first-line chemotherapy (1.2).
DrugBank Targets:
16
1. B-lymphocyte antigen CD20;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. Complement C1s subcomponent;9. High affinity immunoglobulin gamma Fc receptor I;10. Low affinity immunoglobulin gamma Fc region receptor II-a;11. Low affinity immunoglobulin gamma Fc region receptor II-b;12. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:
18
Target: CD20 antigen --> Y-90
Action: beta emission causes damage
FDA: Ibritumomab tiuxetan binds specifically to the CD20 antigen (human B-lymphocyte-restricted differentiation antigen,Bp35). The apparent affinity (KD) of ibritumomab tiuxetan for the CD20 antigen ranges between approximately 14 to18 nM. The CD20 antigen is expressed on pre-B and mature B lymphocytes and on > 90% of B-cell non-Hodgkinâslymphomas (NHL). The CD20 antigen is not shed from the cell surface and does not internalize upon antibody binding.The chelate tiuxetan, which tightly binds Y-90, is covalently linked to ibritumomab. The beta emission from Y-90induces cellular damage by the formation of free radicals in the target and neighboring cells.Ibritumomab tiuxetan binding was observed in vitro on lymphoid cells of the bone marrow, lymph node, thymus, red andwhite pulp of the spleen, and lymphoid follicles of the tonsil, as well as lymphoid nodules of other organs such as thelarge and small intestines.
|
| 25 |
|
Zydelig
18
49
|
IDELALISIB |
Gilead |
July 2014 |
Disease/s that Drug Treats:relapsed CLL, follicular B-cell NHL and small lymphocytic lymphoma
Indications and Usage:
18
Zydelig is a kinase inhibitor indicated for the treatment of patients with: Relapsed chronic lymphocytic leukemia (CLL), in combination withrituximab, in patients for whom rituximab alone would be consideredappropriate therapy due to other co-morbidities. (1.1) Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patientswho have received at least two prior systemic therapies. (1.2) Relapsed small lymphocytic lymphoma (SLL) in patients who havereceived at least two prior systemic therapies. (1.3)Accelerated approval was granted for FL and SLL based on overallresponse rate. Improvement in patient survival or disease relatedsymptoms has not been established. Continued approval for theseindications may be contingent upon verification of clinical benefit inconfirmatory trials.
DrugBank Targets:
16
1. Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta isoform (P110δ)
Mechanism of Action:
18
Target: PI3Kδ kinase
Action: inhibitor
FDA: Idelalisib is an inhibitor of PI3Kδ kinase, which is expressed in normal and malignant Bcells.Idelalisib induced apoptosis and inhibited proliferation in cell lines derived frommalignant B-cells and in primary tumor cells. Idelalisib inhibits several cell signalingpathways, including B-cell receptor (BCR) signaling and the CXCR4 and CXCR5signaling, which are involved in trafficking and homing of B-cells to the lymph nodes andbone marrow. Treatment of lymphoma cells with idelalisib resulted in inhibition ofchemotaxis and adhesion, and reduced cell viability.
|
| 26 |
|
Zykadia
18
49
|
CERITINIB |
Novartis |
April 2014 |
Disease/s that Drug Treats:ALK+ metastatic non-small cell lung cancer
Indications and Usage:
18
ZYKADIA is a kinase inhibitor indicated for the treatment of patients withanaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lungcancer (NSCLC) who have progressed on or are intolerant to crizotinib. Thisindication is approved under accelerated approval based on tumor responserate and duration of response. An improvement in survival or disease-relatedsymptoms has not been established. Continued approval for this indicationmay be contingent upon verification and description of clinical benefit inconfirmatory trials. (1) , ZYKADIA is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. (1)
DrugBank Targets:
16
1. ALK tyrosine kinase receptor, ALK tyrosine kinase receptor
Mechanism of Action:
18
Target: ALK, insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1, anaplastic lymphoma kinase (ALK)
Action: kinase inhibitor, highly-selective inhibitor
FDA: Ceritinib is a kinase inhibitor. Targets of ceritinib inhibition identified in either biochemical or cellular assays at clinicallyrelevant concentrations include ALK, insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1.Among these, ceritinib is most active against ALK. Ceritinib inhibited autophosphorylation of ALK, ALK-mediatedphosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells in in vitroand in vivo assays.Ceritinib inhibited the in vitro proliferation of cell lines expressing EML4-ALK and NPM-ALK fusion proteins anddemonstrated dose-dependent inhibition of EML4-ALK-positive NSCLC xenograft growth in mice and rats. Ceritinibexhibited dose-dependent anti-tumor activity in mice bearing EML4-ALK-positive NSCLC xenografts with demonstratedresistance to crizotinib, at concentrations within a clinically relevant range. , Ceritinib is a kinase inhibitor. Targets of ceritinib inhibition identified in either biochemical or cellular assays at clinically relevant concentrations include ALK, insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1. Among these, ceritinib is most active against ALK. Ceritinib inhibited autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells in in vitro and in vivo assays. Ceritinib inhibited the in vitro proliferation of cell lines expressing EML4-ALK and NPM-ALK fusion proteins and demonstrated dose-dependent inhibition of EML4-ALK-positive NSCLC xenograft growth in mice and rats. Ceritinib exhibited dose-dependent anti-tumor activity in mice bearing EML4-ALK-positive NSCLC xenografts with demonstrated resistance to crizotinib, at concentrations within a clinically relevant range.
|
| 27 |
|
Alecensa
18
|
ALECTINIB HYDROCHLORIDE |
Roche |
December 2015 |
Disease/s that Drug Treats:ALK-positive, metastatic non-small cell lung cancer
Indications and Usage:
18
ALECENSA is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. (1)
DrugBank Targets:
16
ALK tyrosine kinase receptor
Mechanism of Action:
18
Target: ALK and RET
Action: kinase inhibitor
FDA: Alectinib is a tyrosine kinase inhibitor that targets ALK and RET. In nonclinical studies, alectinib inhibited ALK phosphorylation and ALK-mediated activation of the downstream signaling proteins STAT3 and AKT, and decreased tumor cell viability in multiple cell lines harboring ALK fusions, amplifications, or activating mutations. The major active metabolite of alectinib, M4, showed similar in vitro potency and activity. Alectinib and M4 demonstrated in vitro and in vivo activity against multiple mutant forms of the ALK enzyme, including some mutations identified in NSCLC tumors in patients who have progressed on crizotinib. In mouse models implanted with tumors carrying ALK fusions, administration of alectinib resulted in antitumor activity and prolonged survival, including in mouse models implanted intracranially with ALK-driven tumor cell lines.
|
Drugs for Lymphosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 990)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
rituximab |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
174722-31-7 |
10201696
|
|
Synonyms:
AntiCD20
IDEC-102
IDEC-C2B8
Ig gamma-1 chain C region
|
Mabthera
MabThera
Rituxan
rituximab
|
|
| 2 |
|
Vinblastine |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
865-21-4 |
241903
13342
|
|
Synonyms:
(2a,2'b,3b,4a,5b)-VINCALEUKOBLASTINE
(2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE
(2xi,3beta,4'beta,19xi)-vincaleukoblastine
(2α,2'β,3β,4α,5β)-vincaleukoblastine
(3aR-(3aalpha,4beta,5beta,5abeta,9(3R*,5S*,7R*,9S*),10bR*,13aalpha))-methyl 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-1H-indolizino(8,1-cd)carbazole-5-carboxylate
143-67-9
1z2b
29060-LE
865-21-4
AC1L21JC
AC1L68D2
AC1MXZJ2
AC-20335
BIDD:PXR0201
Bio-0111
BRD-K01188359-065-02-5
BSPBio_001228
BSPBio_003594
C07201
C46H58N4O9
CCRIS 9002
Cell pharm brand OF vinblastine sulfate
Cellblastin
CHEBI:171516
CHEBI:27375
CHEMBL159
CHEMBL607706
CID13342
CID241903
CID3823887
CID6710780
D08675
DB00570
EG labo brand OF vinblastine sulfate
EINECS 212-734-0
Faulding brand OF vinblastine sulfate
Gastrozepin brand OF vinblastine sulfate
Gry brand OF vinblastine sulfate
Hexal brand OF vinblastine sulfate
HMS2090K05
HSDB 3263
KBio3_003033
Lemblastine
Lemery brand OF vinblastine sulfate
Lilly brand OF vinblastine sulfate
|
LS-1859
LS-187263
MolPort-002-518-262
MolPort-005-910-359
NCGC00022585-04
NCGC00181127-01
NChemBio.2007.10-comp22
nchembio873-comp22
NCI60_004200
NCI-C04842
NDC 0002-1452-01
Neuro_000020
Nincaluicolflastine
NSC 47842
Rozevin
SPBio_000680
Spectrum2_000890
Spectrum3_001994
STOCK1N-38480
Sulfate, vinblastine
UNII-5V9KLZ54CY
Velban
Velbe
Vinblastin
Vinblastin hexal
Vinblastina
Vinblastina (TN)
Vinblastina [Dcit]
Vinblastina [DCIT]
Vinblastina lilly
vinblastine
Vinblastine
Vinblastine (INN)
Vinblastine [INN:BAN]
Vinblastine sulfate
Vinblastine Sulfate
Vinblastinsulfat-gry
Vinblastinum
Vinblastinum [INN-Latin]
Vincaleucoblastin
Vincaleucoblastine
Vincaleukoblastine
Vincoblastine
VLB
VR-8
|
|
| 3 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
6055-19-2, 50-18-0 |
2907
|
|
Synonyms:
(-)-Cyclophosphamide
(+-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
ASTA B518
B 518
B-518
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
BRN 0011744
BSPBio_002099
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
CID2907
Clafen
Claphene
CP
CPA
CTX
CY
Cycloblastin
Cyclophosphamid
cyclophosphamide
Cyclophosphamide
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (+-)-Isomer
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
|
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
DivK1c_000246
EINECS 200-015-4
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
EU-0100238
Genoxal
Hexadrin
HMS2090A12
HSDB 3047
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
Ledoxina
Lopac0_000238
Lopac-C-0768
LS-1302
LS-99787
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI60_002097
NCI-C04900
Neosar
NINDS_000246
NSC 26271
NSC26271
NSC-26271
NSC273033
NSC273034
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra waste number U058
Rcra Waste Number U058
Revimmune
S1217_Selleck
Semdoxan
Sendoxan
Senduxan
SK 20501
SPBio_001071
Spectrum_000858
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
STK177249
STOCK2S-91217
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
|
|
| 4 |
|
Methylprednisolone hemisuccinate |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
2921-57-5 |
|
|
Synonyms:
Methylprednisolone hydrogen succinate
|
Methylprednisolone succinate
|
|
| 5 |
|
Methylprednisolone |
Approved, Vet_approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
83-43-2 |
6741
|
|
Synonyms:
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
1-dehydro-6alpha-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6a-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6-alpha-Methylprednisolone
6a-Methyl-11b,17a,21-triol-1,4-pregnadiene-3,20-dione
6-Methylprednisolone
6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-wyeth
Artisone-Wyeth
Besonia
Bio-0658
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
delta(1)-6alpha-Methylhydrocortisone
Delta(1)-6alpha-Methylhydrocortisone
delta(1)-6a-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
Lemod
LMST02030178
LS-118498
M0639_SIGMA
M1665
Medesone
Medixon
Medlone 21
Medrate
Medric acid
|
Medrol
Medrol (TN)
Medrol adt pak
Medrol Adt Pak
Medrol dosepak
Medrol Dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
MEPRDL
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
methylprednisolone
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
methylprenisolone
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [Dcit]
Metilprednisolone [DCIT]
Metipred
Metrisone
Metrocort
Metysolon
MLS000028541
MLS001148159
MLS002207191
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
Nirypan
Noretona
NSC19987
NSC-19987
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick_622
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Promacortine
Reactenol
S1733_Selleck
SAM002589984
Sieropresol
SMR000058330
Solomet
SPBio_002377
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
δ(1)-6a-methylhydrocortisone
δ(1)-6α-methylhydrocortisone
|
|
| 6 |
|
Prednisone |
Approved, Vet_approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
53-03-2 |
5865
|
|
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17a,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17α,21-diol-3,11,20-trione
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
Acis brand OF prednisone
ACon0_000082
ACon1_000297
Adasone
AI3-52939
Ancortone
apo-Prednisone
Apo-prednisone
Apo-Prednisone
Apotex brand OF prednisone
Aventis brand OF prednisone
Betapar
Bicortone
Bio-0649
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
C07370
C21H26O5
Cartancyl
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
CPD001227202
Cutason
Dacorten
Dacortin
DB00635
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
delta cortelan
Delta Cortelan
Delta E
Delta E.
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
Delta-cortelan
Delta-Cortelan
Deltacortene
delta-Cortisone
Deltacortisone
Delta-cortisone
delta-Cortone
Deltacortone
Delta-cortone
Delta-dome
Delta-Dome
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Diadreson
Di-Adreson
Diba brand OF prednisone
Econosone
EINECS 200-160-3
Encorton
Encortone
Enkortolon
Enkorton
Fawns and mcallan brand OF prednisone
Fernisone
Ferring brand OF prednisone
Fiasone
GALENpharma brand OF prednisone
Halsey drug brand OF prednisone
Hexal brand OF prednisone
HMS1568O15
HMS2090J13
|
Hoechst brand OF prednisone
Hostacortin
HSDB 3168
ICN brand OF prednisone
Incocortyl
In-Sone
Juvason
Kortancyl
Lichtenstein brand OF prednisone
Liquid pred
Liquid Pred
Lisacort
LMST02030180
Lodotra
LS-1325
MEGxm0_000443
Me-Korti
Merck brand OF prednisone
Merz brand OF prednisone
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
Mibe brand OF prednisone
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI60_000008
NCI-C04897
Nisona
Nizon
Novoprednisone
NSC 10023
NSC10023
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Pharmacia brand OF prednisone
PRD
Precort
Predeltin
Predni tablinen
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Predniment
Prednison
Prednison acsis
Prednison galen
Prednison hexal
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone [INN:BAN]
Prednisone Intensol
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick_405
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
Schering-plough brand OF prednisone
Seatrace brand OF prednisone
Servisone
SK-Prednisone
SMR000718760
SMR001227202
Solvay brand OF prednisone
Sone
SPBio_002214
Sterapred
Supercortil
Trommsdorff brand OF prednisone
U 6020
Ultracorten
Ultracortene
UNII-VB0R961HZT
Winpred
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Wojtab
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
ZINC03875357
|
|
| 7 |
|
Prednisolone phosphate |
Approved, Vet_approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
302-25-0 |
|
|
Synonyms:
Prednisolone 21-(dihydrogen phosphate)
Prednisolone 21-monophosphate
|
Prednisolone 21-phosphate
|
|
| 8 |
|
Prednisolone |
Approved, Vet_approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
50-24-8 |
5755
|
|
Synonyms:
(11b)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11β)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11b,17a,21-triol-3,20-dione
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-pregnadiene-11β,17α,21-triol-3,20-dione
1,4-Pregnadiene-11β,17α,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11b,17a,21-triol
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1,4-pregnadiene-3,20-dione-11β,17α,21-triol
1,4-Pregnadiene-3,20-dione-11β,17α,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11b,17a,21-Trihydroxy-1,4-pregnadiene
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
Bio-0666
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
Codelcortone
Co-Hydeltra
CO-Hydeltra
component of Ataraxoid
component of K-Predne-Dome
Cordrol
Cortalone
Cotogesic
Cotolone
CPD000718761
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
delta(1)-Cortisol
delta(1)-Dehydrocortisol
Delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
Delta(1)-dehydrohydrocortisone
Delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
Delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Deltacortenol
Deltacortril
Deltacortril Enteric
delta-dehydrocortisol
delta-dehydrohydrocortisone
Delta-Ef-Cortelan
delta-hydrocortisone
Deltahydrocortisone
Deltasolone
Delta-stab
Delta-Stab
Deltisilone
Depo-Medrol
Derpo Pd
Derpo PD
Dexa-Cortidelt hostacortin H
Dexa-Cortidelt Hostacortin H
Di adreson F
Di Adreson F
Di-adreson F
Di-Adreson F
Di-adreson-F
DiAdresonF
Di-Adreson-F
Dicortol
Donisolone
Dydeltrone
Eazolin D
Econopred
Econopred Plus
EINECS 200-021-7
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
Hostacortin H
HSDB 3385
Hydeltra
Hydeltrasol
Hydeltra-Tba
|
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
Inflamase Forte
Inflamase Mild
I-Pred
K 1557
Key-Pred
Klismacort
Lentosone
Lite Pred
LMST02030179
LS-7669
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone acetate
Methylprednisolone Acetate
Meticortelone
Meti-Derm
Metreton
MLS001304083
MLS002154250
MLS002207037
MolPort-002-507-147
M-Predrol
NCGC00179649-01
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
NSC 9120
NSC9120
NSC9900
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
PRDL
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
PRED-G
Predisolone sodium phosphate
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Prednicen
Predni-Dome
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
prednisolone
Prednisolone (anhydrous)
Prednisolone (JP15/USP/INN)
Prednisolone [INN:BAN:JAN]
Prednisolone acetate
Prednisolone Acetate
Prednisolone sodium phosphate
Prednisolone Sodium Phosphate
Prednisolone tebutate
Prednisolone Tebutate
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick_404
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Rolisone
S1737_Selleck
SAM002264639
Scherisolon
SMR000718761
Solone
SPBio_002367
Steran
Sterane
Sterolone
Supercortisol
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-hydrogen
Ultracortene-Hydrogen
UNII-9PHQ9Y1OLM
ZINC03833821
δ(1)-dehydrocortisol
δ(1)-dehydrohydrocortisone
δ(1)-hydrocortisone
|
|
| 9 |
|
Vincristine |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
57-22-7, 2068-78-2 |
5978
|
|
Synonyms:
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
Cellcristin
CHEBI:28445
CID5978
Citomid
D08679
DB00541
EINECS 200-318-1
Farmistin
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
LS-228
Marqibo
NCGC00163700-01
NCI60_026703
NCI-C04864
NSC-67574
Onco TCS
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
Onkocristin
|
PFS, Vincasar
Sulfate, vincristine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristin bristol
Vincristin medac
Vincristina
Vincristina [DCIT]
vincristine
Vincristine (INN)
Vincristine [INN:BAN]
Vincristine sulfate
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristinum
Vincristinum [INN-Latin]
Vincrisul
Vincrstine
Vincrystine
Vinkristin
Vintec
Z-D-Val-lys(Z)-OH
Z-D-Val-Lys(Z)-OH
|
|
| 10 |
|
Methotrexate |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
59-05-2, 1959-05-2 |
126941
|
|
Synonyms:
4-amino-10-Methylfolate
4-amino-10-methylfolic acid
4-amino-10-Methylfolic acid
4-amino-N(10)-Methylpteroylglutamate
4-amino-N(10)-methylpteroylglutamic acid
4-amino-N(10)-Methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Dicesium salt methotrexate
Emtexate
Emtexic acid
Folex
HDMTX
Hydrate, methotrexate
L-Amethopterin
Ledertrexate
Ledertrexic acid
Metatrexan
Methopterin
Methotextrate
Methotrate
Methotrexat
|
Méthotrexate
Methotrexate hydrate
Methotrexate sodium
Methotrexate Sodium
Methotrexate, (D)-isomer
Methotrexate, (DL)-isomer
Methotrexate, dicesium salt
Methotrexate, disodium salt
Methotrexate, sodium salt
Methotrexatum
Methotrexic acid
Methylaminopterin
Methylaminopterinum
Metotrexato
Mexate
MTX
N-[4-[[(2,4-diamino-6-Pteridinyl)methyl]methylamino]benzoyl]-L-glutamate
N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
N-[4-[[(2,4-diamino-6-Pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
N-Bismethylpteroylglutamic acid
N-Bismethylpteroylglutamic Acid
Rheumatrex
Sodium, methotrexate
Trexall
|
|
| 11 |
|
Epirubicin |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
56420-45-2 |
41867
|
|
Synonyms:
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione
4' Epi adriamycin
4' Epi doxorubicin
4' Epi DXR
4' Epiadriamycin
4' Epidoxorubicin
4'-Epiadriamycin
4'-Epi-adriamycin
4'-epidoxorubicin
4'-epi-Doxorubicin
4'-Epidoxorubicin
4'-Epi-doxorubicin
4-Epidoxorubicin
4'-epi-DX
4'-Epi-DXR
56390-09-1
56390-09-1 (hydrochloride)
56420-45-2
57918-25-9
AC1L26NP
AC1Q6JIV
BRN 1445813
C11230
C27H29NO11
CCRIS 2261
Cell pharm brand OF epirubicin
CHEBI:47898
CHEMBL417
CID41867
D07901
DB00445
Ellence
EPI cell
Epiadriamycin
EPIcell
EPI-cell
Epidoxorubicin
Epi-Dx
Epi-DX
Epilem
Epirubicin
|
Epirubicin (INN)
Epirubicin [INN:BAN]
Epirubicin hydrochloride
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin
Farmorubicin (TN)
Farmorubicina
Farmorubicine
HSDB 6962
Hydrochloride, epirubicin
IMI 28
IMI28
IMI-28
Kenfarma brand OF epirubicin hydrochloride
Lemery brand OF epirubicin hydrochloride
LS-187190
LS-93992
MLS000759412
NChemBio.2007.10-comp15
NSC 256942
NSC256942
NSC-256942
Pfizer brand OF epirubicin hydrochloride
Pharmorubicin
Pharmorubicin Pfs
Pidorubicin
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
SMR000466308
Triferric doxorubicin
UNII-3Z8479ZZ5X
WP 697
|
|
| 12 |
|
Oxaliplatin |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1 |
|
61825-94-3 |
43805
6857599
5310940
9887054
|
|
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
Oxalatoplatinum
|
oxaliplatin
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
oxaliplatine
oxaliplatino
Oxaliplatino [Spanish]
oxaliplatinum
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
|
|
| 13 |
|
Cisplatin |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
15663-27-1 |
2767
441203
84093
|
|
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
CHEBI:35852
CID441203
Cis Pt II
cis-[PtCl2(NH3)2]
cis-DDP
Cis-DDP
Cis-Diaminedichloroplatinum
cis-diamminedichloridoplatinum(II)
cis-Diamminedichloroplatinum
Cis-Diamminedichloroplatinum
cis-diamminedichloroplatinum(II)
cis-Dichlorodiammineplatinum(II)
Cismaplat
Cisplatine
cisplatino
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
CPD0-1392
CPDC
|
CPDD
DB00515
DDP
DDPT
Diamminedichloroplatinum
EU-0100918
Lederplatin
nchembio773-comp1
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-DDP
Trans-Diaminedichloroplatinum
trans-diamminedichloridoplatinum(II)
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
| 14 |
|
Etoposide |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
33419-42-0 |
36462
|
|
Synonyms:
(−)-etoposide
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-b-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-β-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4-Demethylepipodophyllotoxin b-D-ethylideneglucoside
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4-demethylepipodophyllotoxin β-D-ethylideneglucoside
4-Demethylepipodophyllotoxin β-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-b-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-β-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
alpha-D-Glucopyranosyl isomer etoposide
Ambap33419-42-0
Baxter brand OF etoposide
Baxter oncology brand OF etoposide
Bio1_000489
Bio1_000978
Bio1_001467
BPBio1_000673
BRD-K37798499-001-02-5
Bristol myers brand OF etoposide
Bristol myers squibb brand OF etoposide
Bristol-myers brand OF etoposide
Bristol-myers squibb brand OF etoposide
BSPBio_000611
C01576
CCRIS 2392
Celltop
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl epipodophyllotoxin ethylidine glucoside
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
Eposin, Vepesid, VP-16, Toposar, Etoposide
eto GRY
eto-GRY
Etomedac
ETOP
Etopol
Etopophos
Etopophos (phosphate salt)
Etopos
|
etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposide pierre fabre
Etoposide teva
Etoposide, (5a alpha)-isomer
Etoposide, (5a alpha,9 alpha)-isomer
Etoposide, (5S)-isomer
Etoposide, alpha D glucopyranosyl isomer
Etoposide, alpha-D-glucopyranosyl isomer
Etoposido
Etoposido [INN-Spanish]
etoposido Ferrer farma
Etoposidum
Etoposidum [INN-Latin]
Etosid
Exitop
Ferrer brand OF etoposide
Gry brand OF etoposide
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
Lastet
Lemery brand OF etoposide
LS-1214
Medac brand OF etoposide
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
nchembio.573-comp8
nchembio873-comp2
NK 171
Novartis brand OF etoposide
NSC 141540
NSC141540
NSC-141540
Onkoposid
Onkoworks brand OF etoposide
Pharmachemie brand OF etoposide
Pierre fabre brand OF etoposide
Prasfarma brand OF etoposide
Prestwick_211
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Riboposid
Ribosepharm brand OF etoposide
S1225_Selleck
SAM001246880
Sanfer brand OF etoposide
SMR000112002
SPBio_002532
ST056353
Tedec meiji brand OF etoposide
Teva brand OF etoposide
Toposar
trans-Etoposide
UNII-6PLQ3CP4P3
Vepesid
VePesid
VePESID (TN)
Vepesid J
Vepeside
Vépéside sandoz
Vépéside-sandoz
VP 16
VP 16 (pharmaceutical)
VP 16213
VP 16-213
VP-16
VP-16-213
ZINC03830818
ZINC03938684
Zuyeyidal
|
|
| 15 |
|
Cytarabine |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
147-94-4 |
6253
|
|
Synonyms:
(beta-D-Arabinofuranosyl)cytosine
1-.beta.-D-arabinofuranosyl-cytosine
147-94-4
1-Arabinofuranosylcytosine
1-b-D-Arabinofuranosylcytosine
1beta -Arabinofuranasylcytosine
1-beta -D-Arabinofaranosylcytosine
1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1beta -D-Arabinofuranosylcytosine
1-beta -D-Arabinofuranosylcytosine
1beta -D-Arabinosylcytosine
1beta-Arabinofuranasylcytosine
1-beta-D-Arabinofaranosylcytosine
1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosyl-cytosine
1-beta-D-Arabinofuranosylcytosine, cytosine arabinoside
1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside
1beta-D-Arabinosylcytosine
1-beta-D-Arabinosylcytosine
1-beta-D-Arabinosyl-cytosine
1-β-D-arabinofuranosylcytosine
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl- [CAS]
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl
30399_FLUKA
4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-amino-1-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidin
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]
4-amino-1-Arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
4-amino-1-b-D-Arabinofuranosyl-2(1H)-pyrimidinone
4-amino-1-b-D-Arabinofuranosyl-2-(1H)-pyrimidinone
4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]
4-amino-1-beta-D-Arabinofuranosyl-2(1H)-pyrimidinone
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone
4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
4-amino-1-beta-D-Arabinofuranosylpyrimidin-2(1H)-one
4-amino-1-β-D-arabinofuranosyl-2(1H)-pyrimidinone
69-74-9 (hydrochloride)
AC-1075
AC1L1M4F
AC1Q52OJ
AI3-52329
Alexan
AR3
Arabinocytidine
Arabinofuranosylcytosine
Arabinoside, cytosine
Arabinosyl Cytosine
Arabinosylcytosine
Arabitin
AraC
Ara-C
Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine
Aracytidine
Ara-Cytidine
Aracytin
Aracytine
Arafcyt
beta -Arabinosylcytosine
beta -Cytosine arabinoside
beta -D-Arabinosylcytosine
beta-Ara c
beta-Ara C
beta-Arabinosylcytosine
beta-Cytosine arabinoside
Beta-cytosine arabinoside
beta-D-Arabinosylcytosine
BIDD:GT0371
BIDD:PXR0139
BTB15125
C02961
C1768_SIGMA
C2035
C9H13N3O5
CCRIS 913
CHEBI:28680
CHEMBL803
CHX 3311
CID6253
Citarabina
|
Citarabina [INN-Spanish]
CPD000449317
Cytarabin
Cytarabina
cytarabine
Cytarabine (JP15/USP/INN)
CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9)
Cytarabine [USAN:INN:BAN:JAN]
Cytarabine hydrochloride
cytarabine liposome injection
Cytarabine liposome injection
Cytarabinoside
Cytarabinum
Cytarabinum [INN-Latin]
Cytarbel
Cytonal
Cytosar
Cytosar u
Cytosar-u
CytosarU
Cytosar-U
Cytosine 1-beta-D-arabinofuranoside
Cytosine arabinofuranoside
Cytosine arabinose
Cytosine arabinoside
Cytosine arabinoside (VAN)
Cytosine beta-D-arabinofuranoside
Cytosine beta-D-arabinofuranoside hydrochloride
Cytosine beta-D-arabinoside
Cytosine, beta -D-arabinoside
Cytosine, beta-D-arabinoside
Cytosine-1-b-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside hydrochloride
Cytosine-1-β-D-arabinofuranoside
Cytosinearabinoside
Cytosine-b-D-arabinofuranoside
Cytosine-beta -arabinoside
Cytosine-beta -D-arabinofuranoside
Cytosine-beta-arabinoside
Cytosine-beta-D-arabinofuranoside
cytosine-β-D-arabinofuranoside
Cytosine-β-D-arabinofuranoside
D00168
DB00987
Depocyt
Depocyt (liposomal)
Depocyt (TN)
Depocyte
DepoCyte
EINECS 205-705-9
Erpalfa
FT-0082880
HMS2051K19
HMS2090A18
HSDB 3049
Hydrochloride, cytarabine
Intrathecal (injected into the spinal fluid) DepoCyt
Intrathecal cytarabine (also known as ara-C)
Iretin
Lopac0_000316
LS-860
MLS000758310
MLS001066340
MolPort-001-792-509
NCGC00093356-03
NCGC00093356-04
NCGC00093356-05
NCI-C04728
NSC 287459
NSC287459
S1648_Selleck
SAM001247012
SMR000449317
Spongocytidine
SR-01000075773-3
Tarabine
TL8001048
U 19920A
U-19,920
U-19920
Udicil
UNII-04079A1RDZ
ZINC03795098
|
|
| 16 |
|
Gemcitabine |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable |
|
95058-81-4 |
60750
|
|
Synonyms:
103882-84-4
122111-03-9
2',2'-DFDC
2',2'-DiF-dC
2',2'-difluoro-2'-Deoxycytidine
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate
2'-Deoxy-2'-difluorocytidine
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-Hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFdC
DFDC
DFdCyd
Folfugem
Gamcitabine
Gemcel
Gemcin
Gemcitabin
|
Gemcitabina
Gemcitabina [INN-Spanish]
gemcitabine
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer
Gemcitabine, (D-threo-pentafuranosyl)-isomer
Gemcitabinum
Gemcitabinum [INN-Latin]
GemLip
Gemtro
Gemzar
Gemzar (hydrochloride)
GEO
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY188011
LY-188011
NCGC00168784-01
NChemBio.2007.10-comp25
nchembio.573-comp7
nchembio.90-comp2
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
Zefei
ZINC18279854
|
|
| 17 |
|
Doxorubicin |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
23214-92-8 |
31703
|
|
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-hydroxydaunomycin
14-Hydroxydaunomycin
14-hydroxydaunorubicine
14-Hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
adiblastine (hydrochloride salt)
ADM
ADR
adr iablatina (hydrochloride salt)
Adriablastin
Adriablastine
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin semiquinone
Adriamycin Semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (hydrochloride salt)
Adriblastina (TN)
Adriblastine
adriblatina (hydrochloride salt)
Adrimedac
Aerosolized Doxorubicin
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
BPBio1_000502
BRD-K92093830-003-04-3
Bristol-myers squibb brand OF doxorubicin hydrochloride
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
Caelyx
CCRIS 739
Cell pharm brand OF doxorubicin hydrochloride
CHEBI:28748
CHEMBL179
CID31703
Columbia brand OF doxorubicin hydrochloride
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
Doxil
Doxo
doxo Cell
doxo-Cell
Doxolem
doxorubicin
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin HCl
|
Doxorubicin hexal
Doxorubicin hydrochloride
Doxorubicin Hydrochloride
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
DOX-SL
EINECS 245-495-6
Elan brand OF doxorubicin hydrochloride
Farmablastina (hydrochloride salt)
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
FI 106
Hexal brand OF doxorubicin hydrochloride
HMS2089H06
HSDB 3070
Hydrochloride, doxorubicin
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
LMPK13050001
LS-1029
LS-165655
Medac brand OF doxorubicin hydrochloride
MLS000759533
Myocet
NChemBio.2007.10-comp13
nchembio809-comp5
NCI-C01514
NDC 38242-874
Neocorp brand OF doxorubicin hydrochloride
NIOSH/JT9100000
NSC 123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
Tedec meiji brand OF doxorubicin hydrochloride
ThermoDox
TLC D-99
Triferric doxorubicin
UNII-80168379AG
Urokit doxo cell
Urokit doxo-cell
|
|
| 18 |
|
Dexamethasone acetate |
Approved, Investigational, Vet_approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
1177-87-3 |
|
|
Synonyms:
16alpha-Methyl-9alpha-fluoroprednisolone 21-acetate
9alpha-Fluoro-16alpha-methylprednisolone acetate
Dexamethasone 21-acetate
|
Dexamethasone acetate anhydrous
Dexamethasone acetate, anhydrous
Dexamethasoni acetas
|
|
| 19 |
|
Dexamethasone |
Approved, Investigational, Vet_approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
50-02-2 |
5743
|
|
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
137098-19-2
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16a-Methyl-9a-fluoro-1-dehydrocortisol
16α-methyl-9α-fluoro-1-dehydrocortisol
16α-Methyl-9α-fluoro-1-dehydrocortisol
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-dehydro-16alpha -Methyl-9alpha -fluorohydrocortisone
1-dehydro-16alpha-Methyl-9alpha-fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-dehydro-16a-Methyl-9a-fluorohydrocortisone
1-dehydro-16α-methyl-9α-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9a-fluoro-16a-Methylprednisolone
9a-fluoro-16BETA-METHYLPREDNISOLONE
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -fluoro-16alpha -Methylprednisolone
9alpha-fluoro-16alpha-Methylprednisolone
9alpha-fluoro-16alpha-Methyl-prednisolone
9-alpha-fluoro-16-alpha-Methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9-fluoro-11,17,21-Trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-fluoro-11alpha -Methylpregna-1,4-diene-3,20-dione
9-fluoro-16-Methylprednisolone
9α-fluoro-16α-methylprednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
Adexone
Aeroseb-D
Aeroseb-dex
Aeroseb-Dex
AI3-50934
Ak dex OPH otic soln 0.1%
Alcon brand OF dexamethasone
Alcon Brand of Dexamethasone
alpha -fluoro-16-alpha -Methylcortisol
Anaflogistico
Aphtasolon
Aphthasolone
apo-Dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (veterinary)
Azium (Veterinary)
BIDD:ER0494
BIDD:PXR0060
Bisu Ds
Bisu DS
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
C15643
C22H29FO5
Calonat
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
Corson
Corsone
Cortisumman
CPD001227192
CPD-10549
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-La
Decadron-LA
Decagel
Decaject
Decaject l.a.
Decaject L.A.
Decaject-l.a.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
Delta1-9alpha-fluoro-16alpha-Methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [Dcit]
Desametasone [DCIT]
Desamethasone
Desameton
Deseronil
DEX
Dexa
DEXA
Dexa mamallet
Dexa Mamallet
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexa-cortidelt
Dexa-Cortidelt
Dexacortin
Dexa-cortisyl
Dexa-Cortisyl
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexa-Mamallet
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
Dexameth
Dexamethansone
dexamethasone
Dexamethasone
Dexamethasone (JP15/USP/INN)
|
Dexamethasone [INN:BAN:JAN]
Dexamethasone acetate
Dexamethasone Acetate
Dexamethasone alcohol
Dexamethasone Alcohol
Dexamethasone base
Dexamethasone Base
Dexamethasone intensol
Dexamethasone Intensol
Dexamethasone sodium phosphate
Dexamethasone Sodium Phosphate
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexa-scheroson
Dexa-Scheroson
Dexa-sine
Dexa-Sine
Dexason
Dexasone
Dexasone 0.5MG
Dexasone 0.75MG
Dexasone 4MG
Dexasporin
Dex-ide
Dex-Ide
Dexinolon
Dexinoral
Dexone
Dexone 0.5
DEXONE 0.5
Dexone 0.75
DEXONE 0.75
Dexone 1.5
DEXONE 1.5
Dexone 4
DEXONE 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
DXM
Dxms
DXMS
ECR brand OF dexamethasone
ECR Brand of Dexamethasone
EINECS 200-003-9
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy brand OF dexamethasone
Foy Brand of Dexamethasone
FT-0080377
Gammacorten
Hexadecadrol
Hexadrol
Hexadrol elixir
Hexadrol Elixir
Hexadrol Tablets
Hl-dex
Hl-Dex
HL-Dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
I06-1196
ICN brand OF dexamethasone
ICN Brand of Dexamethasone
IontoDex
isopto-Dex
Isopto-Dex
Lokalison F
Loverine
LS-7300
Luxazone
Maxidex
Maxidex ont 0.1%
Maxidex sus 0.1%
Maxitrol
Mediamethasone
Merck brand OF dexamethasone
Merck Brand of Dexamethasone
Merz brand 1 OF dexamethasone
Merz Brand 1 of Dexamethasone
Merz brand 2 OF dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MK 125
MLS001055412
MLS001332507
MLS001332508
MolMap_000018
MolPort-003-846-433
Mymethasone
Naquasone (veterinary)
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
nchembio809-comp2
NCI60_003067
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
NSC 34521
NSC34521
Ocu-trol
Ocu-Trol
Oradexon
OTO-104
Pet derm III
Pet Derm Iii
Pet Derm III
Pet-Derm Iii
PHL-Dexamethasone
PMS Dexamethasone elixir 0.5mg/5ML
PMS-Dexamethasone
Policort
Posurdex
Prednisolon F
Prednisolone F
Prodex
S1322_Selleck
SAM002548948
Sandoz dexamethasone
SGCUT00126
Sk-Dexamethasone
SK-Dexamethasone
SMP1_000092
SMR000857119
SMR001227192
Spectrum5_002019
Spoloven
ST50307091
Sunia sol D
Sunia Sol D
Superprednol
TL8003317
to_000038
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
|
|
| 20 |
|
Hydroxocobalamin |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1 |
|
13422-51-0 |
11953898
44475014
|
|
Synonyms:
13422-51-0
22465-48-1
78091-12-0
8017-22-9
a-(5,6-Dimethylbenzimidazolyl)hydroxocobamide
Acti-B12
alpha Cobione
alpha-(5,6-Dimethylbenzimidazolyl)hydroxocobamide
AlphaRedisol
AlphaRedisol (TN)
Axion
Axlon
Benzimidazolyl ribofuranosyl phosphate deriv.
C08230
C62H85CoN13O15P
CHEBI:27786
CHEMBL1200742
CHEMBL235822
CID11622291
CID11953898
CID5460373
CID6433575
CID6474319
Ciplamin H
Coalpha-[alpha-(5,6-dimethylbenzimidazolyl)]-Cobeta-hydroxocobamide
Cobalex
Cobalin H
Cobinamide dihydroxide dihydrogen phosphate (ester), mono(inner salt), 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole
Cobinamide hydroxide phosphate 3'-ester with 5,6-dimethyl-1-a-D-ribofuranosylbenzimidazole inner salt
Cobinamide hydroxide phosphate 3'-ester with 5,6-dimethyl-1-alpha-delta-ribofuranosylbenzimidazole inner salt
Cobinamide hydroxide phosphate 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole inner salt
Cobinamide, Co-hydroxy-, dihydrogen phosphate (ester), inner salt, 3'-ester with (5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole-kappaN3)
Cobinamide, Co-hydroxy-, f-(dihydrogen phosphate), inner salt, 3'-ester with (5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole-kappaN3)
Cobinamide, dihydroxide, dihydrogen phosphate (ester), mono (inner salt), 3'- ester with 5,6-dimethyl-1-alpha-D-ribofuranosylbenzimidazole
Cobinamide, dihydroxide, dihydrogen phosphate (ester), mono(inner salt), 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole
Cobinamide, hydroxide, dihydrogen phosphate (ester), inner salt, 3'-ester with 5,6-dimethyl-1-alpha-D-ribofuranosyl-1H-benzimidazole
Codroxomin
Cyanokit
Cyanokit (TN)
D01027
DB00200
Depogamma
Docclan
Docelan
Docelvita
Docevita
Droxomin
Ducobee hy
Ducobee-Hy
Duradoce
Duralta-12
EINECS 236-533-2
Hidroxocobalamina
Hidroxocobalamina [INN-Spanish]
HSDB 3342
Hydro Cobex
|
Hydrobamine
Hydrocobalamin
Hydrogrisevit
Hydrovit
Hydroxocobalamin
Hydroxo-cobalamin
HYDROXOCOBALAMIN
Hydroxocobalamin (JAN/USP/INN)
Hydroxocobalamin [USAN:INN:BAN:JAN]
Hydroxocobalamin acetate
Hydroxocobalamin anhydrous
Hydroxocobalamin monohydrochloride
Hydroxocobalamin Vitamin B12
Hydroxocobalamin(alkaline soln.), OH- replaces CN- in Cyanocobalamin)
Hydroxocobalaminacetat
Hydroxocobalamine
Hydroxocobalamine [INN-French]
Hydroxocobalaminum
Hydroxocobalaminum [INN-Latin]
Hydroxocobalaminum anhydrous
Hydroxocobemine
Hydroxomin
Hydroxy Cobal
Hydroxy vitamin B12
Hydroxycob(lll)alamin
Hydroxycobalamin
Hydroxycobalamine
Hyxobamine
Idrogrisevit
Idrossocobalamina
Idrossocobalamina [DCIT]
LS-54607
Lyovit-H
Neo-Betalin 12
Neo-cytamen
Neo-macrabin
Neo-rojamin
Ohb12
OH-Cbl
OH-CBL
OH-Duphar
Oxobemin
Oxolamine (arcum)
Primabalt RP
Redisol-H
S1668_Selleck
Sytobex-H
UNII-Q40X8H422O
Vibeden
Vitadurin
Vitamin B(sub 12a)
Vitamin B12a
vitamin B-12b
Vitamin b-12b
Vitamin B12b
Vitamin B-12b
|
|
| 21 |
|
Iron |
Approved |
Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable |
|
7439-89-6 |
23925
|
|
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
Ancor B
Ancor en 80/150
armco Iron
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
ATW 230
ATW 432
C00023
C3518_SIAL
C3518_SIGMA
Carbonyl iron
CCRIS 1580
CHEBI:18248
CID23925
Copy Powder CS 105-175
D007501
DB01592
Diseases (animal), iron overload
Diseases, iron overload
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Ed-In-Sol
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
Eisen
Electrolytic iron
F 60 (metal)
Fe
FE
FE (II) ion
Fe(2+)
Fe(II)
Fe1+
|
Fe-40
fer
Feronate
Ferretts
Ferro-Caps
Ferro-Time
Ferrous ion
ferrous iron
Ferrousal
Ferrovac e
Ferrovac E
Ferrum
Ferrum metallicum
FT 3 (element)
GS 6
Hematite
Hemocyte
HF 2 (element)
hierro
Hierro
HL (iron)
Hoeganaes ATW 230
Hoeganaes EH
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Infed
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron ion(2+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, reduced
Limonite
LOHA
LS-3196
Magnetite
Malleable iron
Metopirone
Metyrapone
MolPort-003-925-001
NC 100
PZh1M1
PZh-1M3
PZh-2
PZh2M
PZH2m
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
PZHO
Reduced iron
Remko
Siderol
Suy-b 2
SUY-B 2
Taconite
UNII-E1UOL152H7
Venofer
Vitedyn-Slo
Wrought iron
Yieronia
|
|
| 22 |
|
Methylcobalamin |
Approved, Experimental, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1 |
|
13422-55-4 |
|
|
Synonyms:
Co-methylcobalamin
CO-METHYLCOBALAMIN
MeCbl
mecobalamin
|
Mecobalamin
methyl(III)cobalamin
Methyl(III)cobalamin
Methylcobalamin
|
|
| 23 |
|
leucovorin |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
58-05-9 |
6006
143
|
|
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R,S)-5-Formyltetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-formyltetrahydrofolic acid
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
Acid, folinic
Acide folinique
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
Citrovorum factor
Factor, citrovorum
folinate
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
|
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monosodium salt
Leucovorinum
Leukovorin
Leukovorum
Levoleucovorin
L-leucovorin
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
Rescuvolin
Welcovorin
Wellcovorin
|
|
| 24 |
|
Ifosfamide |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
3778-73-2 |
3690
|
|
Synonyms:
(+-)-Ifosfamid
(+-)-Ifosphamide
(+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
(D,L)-Ifosfamide
(R,S)-Ifosphamide
(R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
{3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd
2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI)
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
3,} 2-oxazaphosphorine oxide
36341-88-5
3778-73-2
84711-20-6
A 4942
AB00513932
AC1L1GHW
AC-2113
Ambap3778-73-2
Asta Z 4942
ASTA Z 4942
BPBio1_000865
BRN 0611835
BSPBio_000785
C07047
CAS-3778-73-2
CCRIS 352
CHEBI:5864
CHEMBL1024
CID3690
Cyfos
D00343
D007069
DB01181
EINECS 223-237-3
HMS1570H07
HMS2090M12
HMS2093N07
Holoxan
Holoxan 1000
HSDB 7023
I06-0494
Ifex
IFEX (TN)
Ifosfamid
Ifosfamida
Ifosfamida [INN-Spanish]
ifosfamide
Ifosfamide (JAN/USP/INN)
Ifosfamide [USAN:INN:BAN:JAN]
Ifosfamide sterile
|
Ifosfamide Sterile
Ifosfamidum
Ifosfamidum [INN-Latin]
Ifosphamide
Ifsofamide
Iphosphamid
Iphosphamid(e)
Iphosphamide
I-phosphamide
I-Phosphamide
iso Endoxan
Iso Endoxan
iso-Endoxan
Isoendoxan
Iso-Endoxan
Isofosfamide
Isophosphamide
isosfamide
Isosfamide
LS-102
LS-99799
Mitoxana
Mitoxana, Ifex, Ifosfamide
MJF 9325
MJF-9325
MLS002154021
MolPort-003-666-704
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide
N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine
N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide
Naxamide
NCGC00016639-01
NCGC00179435-01
NCI60_000233
NCI-C01638
NPFAPI-04
NSC 109,724
NSC 109724
NSC109,724
NSC-109,724
NSC109724
NSC-109724
Prestwick0_000833
Prestwick1_000833
Prestwick2_000833
Prestwick3_000833
S1302_Selleck
SMR001233348
SPBio_002706
STL058690
UNII-UM20QQM95Y
WLN: T6NPOTJ AM2G BO B2G
Z 4942
Z4942
Z-4942
|
|
| 25 |
|
Entecavir |
Approved, Investigational |
Phase 4,Phase 2,Not Applicable |
|
142217-69-4 |
153941
|
|
Synonyms:
142217-69-4
209216-23-9
2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6H-purin-6-one--water (1/1)
2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3H-purin-6-one
6-H-Purin-6-one-,2-amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]
9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)guanine monohydrate
AB1004838
AC-1593
AC1L4BEC
Anhydrous entecavir
Baraclude
Baraclude (TN)
BMS-200475
CHEBI:473990
CHEBI:59902
CHEMBL713
CID153941
D04008
|
D07896
DB00442
Entecavir
Entecavir (anhydrous)
Entecavir (INN)
Entecavir (USAN)
Entecavir anhydrous
Entecavir hydrate
Entecavir hydrate (JAN)
entecavir monohydrate
Entecavirum
ETV
FT-0083013
MolPort-005-942-963
S2128_Selleck
SBB066120
SQ-34676
TL8000933
ZINC03802690
|
|
| 26 |
|
Fosaprepitant |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
172673-20-0 |
219090
|
|
Synonyms:
Emend for injection
Fosaprépitant
Fosaprepitant dimeglumine
|
Fosaprepitantum
L-758,298
L-758298
|
|
| 27 |
|
Aprepitant |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
170729-80-3 |
6918365
151165
|
|
Synonyms:
(1-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-3-(fluoro)phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methylmorpholine
(2R)-(1R)-3,5-Bis(trifluoromethylphenyl)ethoxy)-(3S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazole)methyl-morpholine
170729-80-3
221350-96-5
3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-Delta(2)-1,2,4-triazolin-5-one
3-(((2R,3S)-3-(P-Fluorophenyl)-2-(((alphar)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(2)-1,2,4-triazolin-5-one
3-(((2R,3S)-3-(P-Fluorophenyl)-2-(((alphar)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-Delta(2)-1,2,4-triazolin-5-one
3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(sup 2)-1,2,4-triazolin-5-one
3-(((2R,3S)-3-(P-Fluorophenyl)-2-(((alphar)-a-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(2)-1,2,4-triazolin-5-one
3-(((2R,3S)-3-(P-Fluorophenyl)-2-(((alphar)-a-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-δ(2)-1,2,4-triazolin-5-one
3-(((2R,3S)-3-(P-Fluorophenyl)-2-(((alphar)-α-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-δ(2)-1,2,4-triazolin-5-one
5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one
5-[[(2S,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one
5-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-one
AC1L45SL
AC1OCFCG
Aprepitant
Aprépitant
Aprepitant (JAN/USAN/INN)
Aprepitant [USAN]
Aprepitantum
CHEBI:323967
CHEBI:499361
CHEMBL135613
CHEMBL1471
CHEMBL249465
|
CID11214788
CID11318675
CID151165
CID6918365
CID9936947
CID9936948
D02968
DB00673
Emend
Emend (TN)
HMS2090N12
I06-1151
L 754030
L-754030
LS-156477
MK 0869
MK 869
MK-0517
MK-0869
MK-869
MK-869, L-754030, Emend, Aprepitant
MolPort-006-392-367
NCGC00181785-01
ONO-7436
S1189_Selleck
UNII-1NF15YR6UY
|
|
| 28 |
|
Clarithromycin |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
81103-11-9 |
84029
|
|
Synonyms:
(14R)-14-Hydroxyclarithromycin
116836-41-0
6-O-methyl erythromycin
6-O-Methylerythromycin
6-O-Methylerythromycin a
81103-11-9
A-56268
Abbotic
Abbott-56268
AC1L1HJO
AC1L36NJ
AC1NFSZE
AC1NR4MY
AC1NSJWH
AC1O52DV
AC1Q6O1T
AC-6813
Adel
ANX-015
Astromen
BB_NC-1450
Biaxin
Biaxin (TN)
Biaxin filmtab
Biaxin HP
Biaxin XL
Biaxin xl filmtab
Bicrolid
BIDD:GT0200
Bio-0020
BSPBio_003453
C06912
C2220
C30H54O11.C9H19NO2
CCRIS 8833
CHEBI:136451
CHEBI:3732
CHEMBL143
CHEMBL1741
CID10147055
CID10328822
CID11814635
CID11828745
CID11969952
CID4663848
CID489010
CID5284534
CID5311050
CID54688
CID6426662
CID84029
CID9810688
CID9811194
CLA
Clacine
Clambiotic
Claribid
Claricide
Clarith
clarithromycin
CLARITHROMYCIN
Clarithromycin & Interleukin-12
Clarithromycin (JP15/USP/INN)
Clarithromycin [USAN:INN:BAN:JAN]
Clarithromycin extended release
Clarithromycin suspension or tablets
clarithromycina
Clarithromycina
Clarithromycine
Clarithromycine [INN-French]
Clarithromycinum
Clarithromycinum [INN-Latin]
Claritromicina
|
Claritromicina [INN-Spanish]
Clathromycin
CLM & IL-12
CPD000466382
CRL-1605 & Clarithromycin
CTY
Cyllid
Cyllind
D00276
DivK1c_006655
DRG-0099
Helas
Heliclar
HMS1922H09
HMS2051G18
HMS2090O11
HMS2094M05
hydro-2H-pyran-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexame
I05-0074
KBio1_001599
KBio2_000509
KBio2_003077
KBio2_005645
KBio3_002673
KBioGR_001218
KBioSS_000509
Klacid
Klaciped
Klaricid
Klaricid H.P
Klaricid H.P.
Klaricid Pediatric
Klaricid XL
Klarid
Klarin
Klax
Kofron
Lactoferrin B & Clarithromycin
Lactoferrin H & Clarithromycin
LMPK04000014
LS-1812
Mabicrol
Macladin
Maclar
Mavid
MLS000759516
MLS001201751
MLS001424066
MolPort-002-507-425
MolPort-003-845-969
MolPort-005-910-192
MolPort-005-934-146
Naxy
NCGC00178054-01
NSC643733
O(6)-methylerythromycin
SAM001246748
SDP-015
SMR000466382
SPBio_001855
SpecPlus_000559
Spectrum_000089
SPECTRUM1504231
Spectrum2_001668
Spectrum3_001667
Spectrum4_000629
Spectrum5_001729
STK801952
TE031
TE-031
UNII-H1250JIK0A
Veclam
Zeclar
|
|
| 29 |
|
Metronidazole |
Approved |
Phase 4,Phase 3,Phase 2 |
|
443-48-1 |
4173
|
|
Synonyms:
1-(2-hydroxy-1-ethyl)-2-methyl-5-nitroimidazole
1-(2-Hydroxy-1-ethyl)-2-methyl-5-nitroimidazole
1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole
1-(2-Hydroxyethyl)-2-methyl-5-nitroimidazole
1-(beta-Ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(beta-Hydroxyethyl)-2-methyl-5-nitroimidazole
1-(beta-Oxyethyl)-2-methyl-5-nitroimidazole
1-(b-Ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(b-Hydroxyethyl)-2-methyl-5-nitroimidazole
1-(b-Oxyethyl)-2-methyl-5-nitroimidazole
1-(β-ethylol)-2-methyl-5-nitro-3-azapyrrole
1-(β-hydroxyethyl)-2-methyl-5-nitroimidazole
1-(β-oxyethyl)-2-methyl-5-nitroimidazole
1-Hydroxyethyl-2-methyl-5-nitroimidazole
2 Methyl 5 nitroimidazole 1 ethanol
2-(2-methyl-5-nitroimidazol-1-yl)ethanol
2-methyl-1-(2-hydroxyethyl)-5-nitroimidazole
2-Methyl-1-(2-hydroxyethyl)-5-nitroimidazole
2-methyl-3-(2-hydroxyethyl)-4-nitroimidazole
2-Methyl-3-(2-hydroxyethyl)-4-nitroimidazole
2-Methyl-5-nitro-1-imidazoleethanol
2-methyl-5-nitroimidazole-1-ethanol
2-Methyl-5-nitroimidazole-1-ethanol
443-48-1
46461_FLUKA
46461_RIEDEL
69198-10-3 (mono-hydrochloride)
99616-64-5
AB00052046
AC-10556
AC1L1HKS
AC1Q2P2Z
Acromona
AKOS000269646
Anagiardil
APMN
Apo-Metronidazole
Arilin
ARONIS24285
Atrivyl
BAS 02983617
BAY-5360
Bayer 5360
BCBcMAP01_000184
Bexon
BIDD:GT0107
Bio-0694
BPBio1_000004
BRD-K52020312-001-05-2
BRN 0611683
BSPBio_000002
BSPBio_002031
CAS-443-48-1
Caswell No. 579AA
CB-01-14 MMX
CCRIS 410
CHEBI:39845
CHEBI:6909
CHEMBL137
CID4173
Clont
CONT
CPD000058175
D00409
Danizol
DB00916
Deflamon
Deflamon-wirkstoff
DivK1c_000007
Efloran
EINECS 207-136-1
Elyzol
Entizol
EPA Pesticide Chemical Code 120401
Eumin
Flagemona
Flagesol
Flagil
Flagyl
Flagyl (TN)
Flagyl 375
Flagyl Er
Flagyl I.V.
Flagyl I.V. RTU
FLAGYL I.V. RTU IN PLASTIC CONTAINER
Flegyl
Florazole
Fossyol
Giatricol
Ginefla vir
Gineflavir
giniflavir
HMS1568A04
HMS1920N19
HMS2051G07
HMS2090B19
HMS2091F14
HMS500A09
HMS547C19
HSDB 3129
Hydrochloride, metronidazole
I14-0667
IDI1_000007
IDR-90105
KBio1_000007
KBio2_001515
KBio2_004083
KBio2_006651
KBio3_001531
KBioGR_000559
KBioSS_001515
Klion
Klont
LS-1264
M0924
M1547_SIGMA
M3761_FLUKA
M3761_SIGMA
M9036_SIGMA
Maybridge1_001999
Meronidal
Methronidazole
Methyl-5-nitroimidazole-1-ethanol
Metric
Metric 21
Metro Cream
Metro Gel
|
METRO I.V
Metro I.V.
Metro I.V. In Plastic Container
MetroCream
Metrodzhil
MetroGel
MetroGel-Vaginal
Metrogel-vaginal (TN)
Metrogyl
Metrolag
MetroLotion
Metrolyl
Metromidol
Metronidaz
Metronidazol
Metronidazol [INN-Spanish]
metronidazole
Metronidazole (JP15/USP/INN)
Metronidazole [USAN:INN:BAN:JAN]
Metronidazole benzoate
Metronidazole hydrochloride
Metronidazole in plastic container
Metronidazole in Plastic Container
Metronidazole monohydrochloride
Metronidazole Monohydrochloride
Metronidazole phosphate
Metronidazole phosphoester
Metronidazole Phosphoester
METRONIDAZOLE USP
Metronidazolo
Metronidazolo [DCIT]
Metronidazolum
Metronidazolum [INN-Latin]
Metrotop
Metrozine
Metryl
Mexibol
Mexibol 'silanes'
MLS000028590
MLS000758286
MolPort-000-141-892
MolPort-002-502-101
Monagyl
Monasin
Monohydrochloride, metronidazole
Nalox
NCGC00016446-01
NCGC00016446-02
NCGC00022059-03
NCGC00022059-04
NCGC00022059-05
NCIOpen2_000337
neo-Tric
NIDA
Nidagel
NINDS_000007
Noritate
Noritate (TN)
Novonidazol
NSC 50364
NSC 69587
NSC50364
NSC-50364
NSC69587
Orvagil
Phosphate, metronidazole
Phosphoester, metronidazole
Prestwick_334
Prestwick0_000081
Prestwick1_000081
Prestwick2_000081
Prestwick3_000081
Protostat
Rathimed
Rosased
RP 8823
RP-8823
S1907_Selleck
SAM001247010
Sanatrichom
Satric
SBB041018
SC 10295
SMP1_000189
SMR000058175
SPBio_000666
SPBio_001941
Spectrum_001035
SPECTRUM1500412
Spectrum2_000883
Spectrum3_000506
Spectrum4_000060
Spectrum5_001289
STK177359
Takimetol
Trichazol
Trichex
Tricho cordes
Trichocide
Tricho-gynaedron
Trichomol
Trichomonacid 'pharmachim'
Trichopal
Trichopol
Tricocet
Tricom
Tricowas B
Trikacide
Trikamon
Trikojol
Trikozol
Trimeks
Trivazol
UNII-140QMO216E
Vagilen
Vagimid
Vandazole
Vertisal
Wagitran
WLN: T5N CNJ A2Q B1 ENW
WLN: T5N CNJA2Q B1 ENW
WLN: T6NTJ DQ ANU1- ET5N CNJ A1 BNW
Zadstat
ZERO/004064
Zidoval
ZINC00113442
|
|
| 30 |
|
Amoxicillin |
Approved, Vet_approved |
Phase 4,Phase 3,Phase 2,Not Applicable |
|
26787-78-0 |
33613
|
|
Synonyms:
(-)-6-(2-Amino-2-(P-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo-(3.2.0)heptane-2-carboxylic acid
(2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
(2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
26787-78-0
33911-69-2
34642-77-8 (mono-hydrochloride salt)
4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-, D- (8CI)
6-(a-amino-4-hydroxyphenylacetamido)Penicillanic acid
6-(D-(-)-alpha-Amino-p-hydroxyphenylacetamido)penicillanic acid
6-(D-(-)-p-Hydroxy-alpha-aminobenzyl)penicillin
6-(D-(-)-P-Hydroxy-alpha-aminobenzyl)penicillin
6-(P-Hydroxy-a-aminophenylacetamido)penicillanate
6-(P-Hydroxy-a-aminophenylacetamido)penicillanic acid
6-(P-Hydroxy-alpha-aminophenylacetamido)penicillanate
6-(p-Hydroxy-alpha-aminophenylacetamido)penicillanic acid
6-(P-Hydroxy-alpha-aminophenylacetamido)penicillanic acid
6-(P-Hydroxy-α-aminophenylacetamido)penicillanate
6-(p-hydroxy-α-aminophenylacetamido)penicillanic acid
6-(P-Hydroxy-α-aminophenylacetamido)penicillanic acid
6-[[amino(4-Hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 9ci
61336-70-7 (TRIHYDRATE)
6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carbonyl
6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carboxylic acid
71447-36-4
81030-75-3
a-amino-P-Hydroxybenzylpenicillin
AC-12263
AC1L1PY2
Actimoxi
Almodan
alpha-amino-P-Hydroxybenzylpenicillin
alpha-Amino-p-hydroxybenzylpenicillin
Ambap26787-78-0
AMC
Amix
Amoclen
Amolin
Amopen
Amopenixin
Amoram
Amox
Amox 250 cap 250MG
Amox 500 cap 500MG
Amox S 125 sus 125mg/5ML
Amox S 250 sus 250mg/5ML
Amoxi
Amoxibiotic
Amoxicaps
Amoxicilina
Amoxicilina [INN-Spanish]
amoxicillanyl
amoxicillin
Amoxicillin
Amoxicillin (anhydrous)
Amoxicillin (INN)
Amoxicillin (TN)
Amoxicillin and clavulanate potassium
Amoxicillin anhydrous
Amoxicillin clariana brand
AMOXICILLIN CRYSTALLINE
Amoxicillin monopotassium salt
Amoxicillin monosodium salt
Amoxicillin pediatric
AMOXICILLIN PEDIATRIC
Amoxicillin sodium
Amoxicillin trihydrate
Amoxicillin Trihydrate
Amoxicillin(usan)
Amoxicillin, (r*)-isomer
Amoxicilline
Amoxicilline [INN]
Amoxicilline [INN-French]
Amoxicillinum
Amoxicillinum [INN-Latin]
Amoxid
Amoxiden
Amoxil
Amoxi-mast
Amoxi-Mast
Amoxivet
Amoxycilin
Amoxycillin
Amoxycillin trihydrate
Amoxycillin Trihydrate
Amoxycillin, ban
Amoxymed
AMPC
Amrit
Anemolin
Anhydrous, amoxicillin
apo-Amoxi
Apo-Amoxi
apo-Amoxi cap 250MG
apo-Amoxi cap 500MG
apo-Amoxi PWR for susp 125mg/5ML
apo-Amoxi PWR for susp 250mg/5ML
apo-Amoxi sugar free
Aspenil
AUGMENTIN '125'
AUGMENTIN '200'
AUGMENTIN '250'
AUGMENTIN '400'
AUGMENTIN '500'
AUGMENTIN '875'
AUGMENTIN es-600
AX
Biomox
BLP 1410
BL-P 1410
|
BPBio1_000499
BRD-K55044200-001-03-9
Bristamox
BRL 2333
BRL-2333
BSPBio_000453
C06827
Cemoxin
CHEBI:2676
CHEBI:53712
CHEMBL1082
CID33613
Clamoxyl
Clamoxyl (SKB)
Clamoxyl g.a.
Clamoxyl parenteral
Clariana brand OF amoxicillin
CPD000058707
D-(-)-alpha-amino-P-Hydroxybenzyl penicillin
D-(-)-alpha-amino-P-Hydroxybenzylpenicillin
D-(-)-alpha-Amino-p-hydroxybenzylpenicillin
D-(alpha-amino-P-Hydroxybenzyl)penicillin
D07452
D-2-amino-2-(4-Hydroxyphenyl)acetamidopenicillanic acid
D-2-Amino-2-(4-hydroxyphenyl)acetamidopenicillanic acid
D-Amoxicillin
DB01060
Delacillin
Dispermox
DisperMox
Efpenix
EINECS 248-003-8
Flemoxin
G.A., clamoxyl
Galenamox
Gen-amoxicillin 250MG
Gen-amoxicillin 500MG
Hiconcil
Histocillin
HMS1569G15
HSDB 3204
Hydroxyampicillin
Ibiamox
Imacillin
Lamoxy
Larotid
LS-149721
Metafarma capsules
Metifarma capsules
MLS000028632
MLS002222248
MolPort-003-981-182
MolPort-005-933-687
Moxacin
Moxal
Moxatag
NCGC00179554-01
Novamoxin cap 250MG
Novamoxin cap 500MG
Novamoxin sus 125mg/5ML
Novamoxin sus 250mg/5ML
NSC 277174
NSC277174
Nu-amoxi cap 250MG
Nu-amoxi cap 500MG
Nu-amoxi sus 125/5ML
Nu-amoxi sus 250mg/5ML
Ospamox
Pamoxicillin
Parenteral, clamoxyl
Penamox
Pfizer brand OF amoxicillin sodium salt
PHL-Amoxicillin
p-Hydroxyampicillin
P-Hydroxyampicillin
Piramox
PMS-Amoxicillin
Polymox
Prestwick_713
Prestwick0_000357
Prestwick1_000357
Prestwick2_000357
Prestwick3_000357
Prevpac
pro Amox PWR for oral susp 125mg/5ML
pro Amox-250 cap 250MG
pro Amox-500 cap 500MG
pro-Amox-250 orl sus 250mg/5ML
R-Hydroxyampicillin
Rimoxallin
Ro 10-8756
Robamox
SAM002264592
Sauracillin
Sawamox PM
SmithKline beecham brand OF amoxicillin sodium salt
SMR000058707
Sodium, amoxicillin
SPBio_002374
Sumox
Tolodina
Trihydrate, amoxicillin
Trimox
Unicillin
Utimox
Vetramox
Wymox
Zimox
α-amino-p-hydroxybenzylpenicillin
α-amino-P-hydroxybenzylpenicillin
|
|
| 31 |
|
Tropisetron |
Approved, Investigational |
Phase 4,Not Applicable |
|
89565-68-4, 105826-92-4 |
5595
|
|
Synonyms:
(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 1H-indole-3-carboxylate
[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-3-carboxylate
AC1LCVDG
C13666
CHEBI:188800
CHEMBL56564
CID656665
D02130
HMS2090D16
ICS-205930
Lopac-T-104
|
MolPort-006-823-819
Navoban
Navoban (TN)
NCGC00015984-01
NCGC00161414-01
Novaban
PDSP1_000776
PDSP2_000764
TKT
tropisetron
Tropisetron (INN)
|
|
| 32 |
|
Daunorubicin |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
20830-81-3 |
30323
|
|
Synonyms:
(+)-Daunomycin
(1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro--6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione
11006-54-5
11048-29-6
1407-15-4
149541-57-1
20830-81-3
23942-76-9
27576-81-4
28020-80-6
AB00514669
AC1L1JCP
AC1Q29OI
Acetyladriamycin
AI3-52942
Anthracyline
Antibiotics from Streptomyces coeruleorubidus
Antibiotics From Streptomyces Coeruleorubidus
BPBio1_000389
BRD-K43389675-003-02-7
BRN 1445583
BSPBio_000353
C01907
CCRIS 914
Cerubidin
Cerubidine
CHEBI:41977
CHEMBL178
CID30323
D07776
Daunamycin
Daunarubicinum
dauno Rubidomycine
Daunoblastin
Daunoblastine
Daunomycin
Daunomycin Hydrochloride
Daunomycin, Hydrochloride
Daunorrubicina
daunorubicin
Daunorubicin
Daunorubicin (INN)
Daunorubicin (liposomal)
|
Daunorubicin [INN:BAN]
Daunorubicin Hcl
DAUNORUBICIN HCL
Daunorubicin hydrochloride
Daunorubicin Hydrochloride
Daunorubicin, Hydrochloride
Daunorubicina
Daunorubicine
Daunorubicinum
Daunorubicinum [INN-Latin]
dauno-Rubidomycine
Dauno-Rubidomycine
Daunoxome
DaunoXome
DaunoXome (TN)
DB00694
DM1
EINECS 244-069-7
FI 6339
FI6339
HMS2089H04
HMS2091K06
HSDB 5095
Hydrochloride, daunorubicin
Leukaemomycin C
LMPK13050002
LS-187381
LS-997
MolPort-002-533-961
NCGC00024246-05
NCGC00024246-06
NCGC00025173-01
NChemBio.2007.10-comp14
nchembio723-comp2
NCI-C04693
NSC 83142
NSC-82151
Ondena
Prestwick3_000487
Rcra Waste No. U059
RCRA waste no. U059
RP 13057
Rp 13057 Hydrochloride
Rubidomycin
Rubidomycin Hydrochloride
Rubomycin
Rubomycin C
Tocris-1467
UNII-ZS7284E0ZP
VS-103
|
|
| 33 |
|
Thioguanine |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
154-42-7 |
2723601
|
|
Synonyms:
154-42-7
2 amino 6 Purinethiol
2 Amino 6 Purinethiol
2-amino 6MP
2-Amino 6MP
2-Amino-1,7-dihydro-6H-purin-6-thion
2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]
2-amino-1,7-dihydro-6H-Purine-6-thione
2-Amino-1,7-dihydro-6H-purine-6-thione
2-amino-1,9-dihydropurine-6-thione
2-amino-1,9-Dihydropurine-6-thione
2-amino-3,7-dihydropurine-6-thione
2-amino-6-Mercaptopurine
2-Amino-6-mercaptopurine
2-amino-6-Merkaptopurin
2-Amino-6-merkaptopurin
2-Amino-6-merkaptopurin [Czech]
2-Amino-6-MP
2-amino-6-Purinethiol
2-Amino-6-purinethiol
2-Amino-9H-purine-6-thiol
2-Aminopurin-6-thiol
2-Aminopurin-6-thiol [Czech]
2-Aminopurine-6(1H)-thione
2-Aminopurine-6-thiol
2-Thioguanine
5580-03-0
6 Thioguanine
6-mercapto-2-Aminopurine
6-Mercapto-2-aminopurine
6-Mercaptoguanine
6-TG
6-Thioguanine
6-Thioguanine (6-TG)
6-Thioguanine, Thioguanine
A4660_SIGMA
A4882_SIGMA
AC-11125
AC1MC379
AI3-26078
AKOS003389499
Anhydrous, thioguanine
BSPBio_001994
BW 5071
C07648
C5H7N5S
CCRIS 8997
CHEBI:136864
CHEMBL727
CID2723601
cMAP_000061
D013866
D08603
DB00352
DivK1c_000428
DX4
EINECS 205-827-2
FT-0083572
glaxo Wellcome brand OF thioguanine
Glaxo Wellcome Brand of Thioguanine
glaxo Wellcome brand OF tioguanine
Glaxo Wellcome Brand of Tioguanine
GlaxoSmithKline brand OF thioguanine
GlaxoSmithKline Brand of Thioguanine
GlaxoSmithKline brand OF tioguanine
GlaxoSmithKline Brand of Tioguanine
Guanine, thio- (VAN)
HMS1921E09
HMS2092M11
HMS501F10
HSDB 2504
I14-1541
IDI1_000428
KBio1_000428
KBio2_000715
KBio2_002476
KBio2_003283
|
KBio2_005044
KBio2_005851
KBio2_007612
KBio3_001494
KBio3_002954
KBioGR_001452
KBioGR_002476
KBioSS_000715
KBioSS_002483
Lanvis
Lanvis (TN)
LS-888
LT00455187
MLS001333131
MLS001333132
MolPort-000-929-106
MolPort-001-813-204
MolPort-003-984-174
NCGC00094792-01
NCGC00094792-02
NCGC00094792-03
NCI60_041643
NCIOpen2_004153
NINDS_000428
NSC 752
NSC752
NSC-752
purine antimetabolite: antimetabolite: inhibits nucleic acid replication
S1774_Selleck
SBB067147
SMP2_000326
SMR000857244
SPBio_000849
Spectrum_000235
SPECTRUM1500573
Spectrum2_000695
Spectrum3_000577
Spectrum4_000926
Spectrum5_001455
ST50298831
T0212
Tabloid
TG
ThG
THG
Thioguanin GSK
thioguanine
Thioguanine
Thioguanine [USAN:BAN]
Thioguanine anhydrous
Thioguanine hemihydrate
Thioguanine Hemihydrate
Thioguanine monosodium salt
Thioguanine Monosodium Salt
Thioguanine tabloid
Thioguanine Tabloid
Thioguanine, anhydrous
ThioguaninGSK
Thioguanin-GSK
Tioguanin
Tioguanina
Tioguanina [INN-Spanish]
Tioguanina wellcome
Tioguanina Wellcome
Tioguanine
Tioguanine (INN)
Tioguanine glaxosmithkline brand
Tioguanine GlaxoSmithKline Brand
Tioguaninum
Tioguaninum [INN-Latin]
UNII-FTK8U1GZNX
UNII-WIX31ZPX66
Wellcome brand OF thioguanine
Wellcome Brand of Thioguanine
Wellcome U3B
WLN: T56 BNM FYM INJ FUS HZ
ZINC18085533
|
|
| 34 |
|
Fludarabine |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
75607-67-9, 21679-14-1 |
30751
|
|
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
21679-14-1
2-F-ara-A
2-F-ARAA
2F-Ara-AMP
2-fluoro ARA-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-Fluoroadenine arabinoside 5'-monophosphate
2-Fluoroadenine arabinoside 5'-monophosphoric acid
2-fluoro-ARA AMP
9 beta-D-Arabinofuranosyl-2-fluoroadenine monophosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
9-β-arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-β-arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-β-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-β-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-β-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-β-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
AC1LCW8I
AC1Q51CF
Beneflur
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
|
CPD000058874
D07966
EINECS 244-525-5
FAMP
FaraA
F-Ara-A
FaraAMP
F-Ara-AMP
Fludara
Fludara, Fludarabine
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine [INN]
Fludarabine 5'-monophosphate
Fludarabine 5'-monophosphoric acid
Fludarabine monophosphate
Fludarabine monophosphoric acid
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
fluoro-Ara-AMP
Fluradosa
Fluradosa (TN)
FT-0082766
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
|
|
| 35 |
|
Dasatinib |
Approved, Investigational |
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable |
|
302962-49-8 |
3062316
|
|
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
(18F)-N-(2-chloro-6-Methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
anh. dasatinib
Anh. dasatinib
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS Dasatinib
BMS354825
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
dasatinib
Dasatinib
Dasatinib (anh.)
dasatinib (anhydrous)
Dasatinib (USAN)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
|
dasatinibum
Dasatinibum
DB01254
EC-000.2122
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-METHYLPHENYL)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-Methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1
NSC732517
NSC-732517
S1021_Selleck
Sprycel
SPRYCEL (TN)
Spyrcel
UNII-X78UG0A0RN
|
|
| 36 |
|
Idarubicin |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
58957-92-9 |
42890
|
|
Synonyms:
(1S,3S)-3-Acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-Acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-|A-l-lyxo-hexopyranoside
(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione
4 Demethoxydaunorubicin
4 Desmethoxydaunorubicin
4-Demethoxydaunomycin
4-Demethoxydaunorubicin
4-Desmethoxydaunorubicin
4-DMD
57852-57-0
57852-57-0 (HYDROCHLORIDE)
58957-92-9
AC1L28SA
AC1Q6JJ4
BRD-K69650333-001-01-1
C26H27NO9
CCRIS 5083
CHEBI:42068
CHEMBL1117
CID42890
D08062
DB01177
DM5
DMDR
EU-0100600
HMS2089D05
Hydrochloride, idarubicin
I 1656
I06-1097
I1656_SIGMA
Idamycin
|
Idamycin PFS
IDARUBICIN
Idarubicin (INN)
Idarubicin [INN:BAN]
Idarubicin Aglycone
Idarubicin Hcl
Idarubicin Hcl Pfs
Idarubicin HCl PFS
idarubicin hydrochloride
Idarubicin hydrochloride
Idarubicin Hydrochloride
Idarubicina
Idarubicina [INN-Spanish]
Idarubicine
Idarubicine [INN-French]
Idarubicinum
Idarubicinum [INN-Latin]
IMI 30
IMI30
IMI-30
KBioSS_002388
Lopac0_000600
LS-94015
MLS000759470
NCGC00093976-01
NCGC00093976-02
NCGC00093976-03
NCGC00093976-04
NSC256439
NSC-256439
SMR000466355
UNII-ZRP63D75JW
Zavedos
Zavedos (TN)
|
|
| 37 |
|
Teniposide |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
29767-20-2 |
34698
|
|
Synonyms:
23362-13-2
29767-20-2
299-36-5
31514-29-1
35317-44-3
4'-demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-b-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-2-thenylidene-β-D-glucopyranoside)
4'-Demethylepipodophyllotoxin thenylidene glucoside
4-Demethylepipodophyllotoxin-.beta.-D-thenylideneglucoside
4'-Demethylepipodophyllotoxin-b-D-thenylidene glucoside
4'-Demethylepipodophyllotoxin-beta-D-thenylidene glucoside
4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside
4'-Demethylepipodophyllotoxin-beta-D-thenylidine glucoside
4'-Demethylepipodophyllotoxin-β-D-thenylidene glucoside
4'-Dimethyl-9-(4,6-O-2-thenyid)-epipodophyllotoxin
55256-09-2
AC1L1K9H
AC1L1S3X
AC1L32H7
AC1L5IF3
AC1L9QDK
AC1NR4S8
AC1O8FOE
AC-759
Ambap29767-20-2
AR-1A6252
AR-1A6526
BRD-A35588707-001-02-2
Bristol myers brand OF teniposide
Bristol myers squibb brand OF teniposide
Bristol-myers brand OF teniposide
Bristol-myers squibb brand OF teniposide
BSPBio_003436
C11153
C32H32O13S
CCRIS 2058
CHEMBL278534
CID107642
CID275784
CID34698
CID452548
CID5284623
CID5396
CID6708778
D02698
DB00444
Demethyl epipodophyllotoxin thenylidine glucoside
Demethyl Epipodophyllotoxin Thenylidine Glucoside
DivK1c_006888
EINECS 249-831-2
Epidophyllotoxin
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside)
|
FT-0080118
HMS1922B15
HMS2093O15
HSDB 6546
I06-2040
KBio1_001832
KBio2_002029
KBio2_004597
KBio2_007165
KBio3_002939
KBioGR_001050
KBioSS_002029
KST-1A3576
KST-1A5976
LS-63999
MLS000766234
MolPort-003-666-525
MolPort-005-940-276
MolPort-006-822-656
NCI60_000540
Neuro_000056
NSC 122819
NSC 12819
NSC122819
NSC-122819
PTG
S1787_Selleck
SMR000528847
SPBio_001773
SpecPlus_000792
Spectrum_001549
SPECTRUM1504094
Spectrum2_001647
Spectrum3_001898
Spectrum4_000585
Spectrum5_001111
Teniposid
teniposide
Téniposide
Teniposide (USAN/INN)
Teniposide [USAN:BAN:INN]
Teniposide, (5a alpha,9 alpha(s*))-isomer
Teniposido
Teniposido [INN-Spanish]
Teniposidum
Teniposidum [INN-Latin]
UNII-957E6438QA
Vee M-26
Veham-Sandoz
Vehem
VM 26
VM-26
Vumon
Vumon (TN)
Vumon, VM-26, Vehem, NSC 122819, Teniposide
|
|
| 38 |
|
Hydrocortisone acetate |
Approved, Vet_approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
50-03-3 |
|
|
Synonyms:
21-O-acetylcortisol
Cortisol 21-acetate
|
Hydrocortisone 21-acetate
|
|
| 39 |
|
Mitoxantrone |
Approved, Investigational |
Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable |
|
65271-80-9 |
4212
|
|
Synonyms:
1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
1,4-DIHYDROXY-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-anthracenedione
1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE
1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone
1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione
1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione
1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon
1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione
1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione
137635-96-2
2fum
5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone
65271-80-9
70476-82-3
70476-82-3 (hydrochloride)
70711-41-0
70711-41-0 (acetate)
70945-62-9
9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)- (9CI)
AB00053716
AC1L1HNY
Acetate, mitoxantrone
AHP brand OF mitoxantrone hydrochloride
Amgen brand OF mitoxantrone hydrochloride
AN-584/42007670
ASTA medica brand OF mitoxantrone hydrochloride
Baxter oncology brand OF mitoxantrone hydrochloride
BIDD:PXR0181
BPBio1_000627
BRD-K21680192-300-05-2
BRD-K21680192-300-07-8
BRN 2795126
BSPBio_000569
BSPBio_003160
C11195
C22H28N4O6
CAS-70476-82-3
CCRIS 7604
CHEBI:50729
CHEMBL58
CID4212
Columbia brand OF mitoxantrone hydrochloride
D08224
DB01204
DHAD
DHAQ
DHAQ (*Diacetate salt*)
DHAQ HCl
Dihydroxyanthraquinone
DivK1c_000516
HMS2090D05
Hydrochloride, mitoxantrone
IDI1_000516
Inibsa brand OF mitoxantrone hydrochloride
KBio1_000516
KBio2_002135
KBio2_004703
KBio2_007271
KBio3_002660
KBioGR_001531
KBioSS_002135
Lederle brand OF mitoxantrone hydrochloride
Liposome Encapsulated Mitoxantrone (LEM)
Lopac0_000779
Lopac-M-6545
LS-20638
Misostol
Misostol (TN)
Mitox
|
Mitoxanthrone
Mitoxantron
Mitoxantrona
Mitoxantrona [INN-Spanish]
mitoxantrone
Mitoxantrone
Mitoxantrone (free base)
Mitoxantrone (INN)
Mitoxantrone [INN]
Mitoxantrone 2HCl
Mitoxantrone acetate
Mitoxantrone dihydrochloride
Mitoxantrone HCl
Mitoxantrone hydrochloride
MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE
MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE
Mitoxantronum
Mitoxantronum [INN-Latin]
Mitozantrone
Mitozantrone hydrochloride
Mitroxone
MIX
MLS002703044
MolPort-003-849-239
NCGC00015693-01
NCGC00015693-02
NCGC00015693-04
NCGC00162251-01
NChemBio.2007.10-comp17
NCI60_002276
NCI60_002535
Neuro_000153
NINDS_000516
Novantron
Novantrone
Novantrone(R) (mitoxantrone for injection concentrate)
NSC 279836
NSC279836
NSC-279836
NSC-287836
NSC299195
NSC-299195
NSC301739
NSC-301739
NSC-301739D
Onkotrone
Pralifan
Prestwick0_000385
Prestwick1_000385
Prestwick2_000385
Prestwick3_000385
Ralenova
S2485_Selleck
SMP2_000179
SMR001549953
SPBio_000756
SPBio_002490
Spectrum_001655
Spectrum2_000908
Spectrum3_001590
Spectrum4_000866
Spectrum5_001205
SR-01000076001
SR-01000076001-7
STK631833
UNII-BZ114NVM5P
VU0244399-2
Wyeth brand OF mitoxantrone hydrochloride
|
|
| 40 |
|
Hydrocortisone |
Approved, Vet_approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
50-23-7 |
5754
|
|
Synonyms:
(11b)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
(11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione
[3H]cortisol
11 Epicortisol
11a-Hydroxycorticosterone
11alpha-Hydroxycorticosterone
11b,17,21-Trihydroxyprogesterone
11b,17a,21-Trihydroxy-4-pregnene-3,20-dione
11beta,17,21-Trihydroxyprogesterone
11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
11beta-hydrocortisone
11beta-Hydrocortisone
11-beta-Hydrocortisone
11beta-Hydroxycortisone
11-beta-Hydroxycortisone
11b-Hydrocortisone
11b-Hydroxycortisone
11-Epicortisol
11-Hydrocortisone
11β,17α,21-trihydroxy-4-pregnene-3,20-dione
11β-hydrocortisone
17a-Hydroxycorticosterone
17alpha-Hydroxycorticosterone
17-Hydroxycorticosterone
2v95
4-Pregnen-11b,17a,21-triol-3,20-dione
4-Pregnen-11beta,17alpha,21-triol-3,20-dione
4-pregnen-11β,17α,21-triol-3,20-dione
4-Pregnen-11β,17α,21-triol-3,20-dione
4-Pregnene-11alpha,21-triol 3,20-dione
4-Pregnene-11b,17a,21-triol-3,20-dione
50-23-7
8056-08-4
80562-38-5
8063-42-1
AC-12902
AC1L1L2B
ACETASOL HC
ACETIC ACID W/ HYDROCORTISONE
Acticort
Acticort (TN)
Aeroseb HC
Aeroseb-HC
AI3-25006
AKOS001582651
Alacort
Ala-cort
Ala-Cort
Ala-scalp
Ala-Scalp
Algicirtis
Alphaderm
Amberin
Anflam
Anti-inflammatory hormone
Anucort
Anucort-HC
Anusol HC
Anusol HC (TN)
Anusol-HC
Aquacort
Aquanil HC
B48448A1-24BA-47CA-8D9E-43E5BC949386
Balneol-hc
Balneol-HC
Barseb HC
Basan-corti
Basan-Corti
Beta-hc
Beta-HC
b-HC
Bio-0648
BPBio1_000544
BRD-K93568044-001-03-1
BSPBio_000494
C00735
C21H30O5
CaldeCORT spray
CaldeCORT Spray
CCRIS 5854
Cetacort
CHEBI:17650
CHEMBL389621
Chronocort
CID5754
Clear aid
Cleiton
Cobadex
Colocort
Colocort (TN)
component of Lubricort
component of Neo-Cort-Dome
component of Otalgine
Compound F
Compound F (kendall)
Corhydron
Cor-oticin
COR-OTICIN
Cortanal
Cor-tar-quin
Cort-dome
Cort-Dome
Cortef
Cortef (TN)
Cortenema
Cortesal
Corticreme
Cortifair
Cortifan
Cortifoam
Cortiment
Cortisol
Cortisol alcohol
Cortisol, Hydrocortisone
Cortisolonum
Cortisporin
Cortisporin otico
Cortisporin Otico
Cortispray
Cortizol
Cortolotion
Cortonema
Cortoxide
Cort-quin
Cortril
CORTRIL
CPD000653523
Cremesone
Cremicort-H
Cutisol
Cyclodextrin-encapsulated hydrocortisone
D00088
DB00741
DB07886
Delacort
Dermacort
Derm-aid
Derm-Aid
Dermaspray
Dermil
Dermocortal
Dermolate
Dihydrocostisone
Dioderm
Dome-cort
Domolene-HC
Drotic
DuoCort
Ef corlin
Efcorbin
Efcortelan
Efcortelin
EINECS 200-020-1
Eldecort
Eldercort
Epicort
Epicortisol
Epiderm H
Esiderm H
EU-0100594
Evacort
Ficortril
Fiocortril
Flexicort
Foille insetti
Foille Insetti
Genacort
Genacort (lotion)
Glycort
gyno-Cortisone
Gyno-Cortisone
H 4001
H0135_SIGMA
H0396_SIGMA
H0888_SIGMA
H3160_SIGMA
|
H4001_SIGMA
H6909_SIGMA
HC
HC #1
HC #4
HC (HYDROCORTISONE)
H-Cort
Heb cort
Heb Cort
Heb-cort
Heb-Cort
Hi-cor
Hidalone
hidro-Colisona
Hidro-Colisona
Hidrocortisona
Hidrocortisona [INN-Spanish]
HMS1569I16
HMS2090M04
HSDB 3339
Hycort
Hycortol
Hycortole
Hydracort
Hydrasson
hydro-Adreson
Hydro-Adreson
hydro-Colisona
Hydro-Colisona
Hydrocort
Hydrocortal
Hydrocorticosterone
hydrocortisone
Hydrocortisone
Hydrocortisone (JP15/USP/INN)
Hydrocortisone [INN:BAN:JAN]
Hydrocortisone acetate
Hydrocortisone alcohol
HYDROCORTISONE AND ACETIC ACID
Hydrocortisone base
Hydrocortisone butyrate
Hydrocortisone free alcohol
Hydrocortisone in absorbase
HYDROCORTISONE IN ABSORBASE
Hydrocortisone sodium phosphate
Hydrocortisone solution
Hydrocortisone valerate
Hydrocortisone, (11 alpha)-isomer
Hydrocortisone, (9 beta,10 alpha,11 alpha)-isomer
Hydrocortisone-Water Soluble
Hydrocortisonum
Hydrocortisonum [INN-Latin]
Hydrocortistab
Hydrocortisyl
Hydrocortone
HYDROCORTONE
hydro-RX
Hydro-RX
Hydroskin
Hydroxycortisone
Hysone
Hytisone
Hytone
Hytone (TN)
Hytone lotion
Idrocortisone
Idrocortisone [DCIT]
Incortin-H
Incortin-hydrogen
Kendall's compound F
Komed HC
Kyypakkaus
Lacticare HC
Lacticare-HC
Lactisona
LMST02030001
Locoid
Lopac0_000594
LS-7439
Lubricort
Maintasone
Medicort
Meusicort
Micort-HC
Mildison
Milliderm
MLS000069609
MLS001148103
MLS002207135
MLS002222189
MolPort-001-794-637
NCGC00022848-06
NCGC00022848-07
NCGC00022848-09
NCGC00022848-12
NCI60_000118
neo-Cort-dome
neo-Cortef
Neo-Cortef
Neosporin-H ear
Neosporin-H Ear
Nogenic HC
NSC 10483
NSC10483
NSC-10483
Nutracort
Nystaform-HC
Ophthocort
Optef
ORLEX HC
Otalgine
Otic-neo-cort-dome
Otobiotic
Otocort
Otosone-F
Pediotic suspension
Pediotic Suspension
Penecort
Permicort
Plenadren
Polcort H
Preparation H hydrocortisone cream
Preparation H Hydrocortisone Cream
Prepcort
Prestwick_265
Prestwick0_000447
Prestwick1_000447
Prestwick2_000447
Prestwick3_000447
Prevex HC
Proctocort
Proctofoam
Proctozone HC
Protocort
Racet
Rectasol-HC
Rectoid
Reichstein's substance m
Reichstein's substance M
Remederm HC
S1696_Selleck
SAM002264617
Sanatison
Scalp-Cort
Scalpicin capilar
Scalpicin Capilar
Schericur
Scheroson F
Sigmacort
Signef
SMP1_000156
SMR000059022
SMR000653523
SPBio_002433
Stie-cort
Stiefcorcil
Synacort
Systral hydrocort
Systral Hydrocort
Tarcortin
Terra-cortril
Texacort
Texacort lotion 25
Timocort
Topicort
Transderma H
Traumaide
U-cort
Uniderm
UNII-WI4X0X7BPJ
UPCMLD-DP133
UPCMLD-DP133:001
Vioform-hydrocortisone
VoSol HC
Vytone
Zenoxone
β-HC
|
|
| 41 |
|
Pegaspargase |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
130167-69-0 |
|
|
Synonyms:
L-asparagine amidohydrolase
Oncaspar
Peg/L-asparaginase
|
Peg-asparaginase
Putative L-asparaginase precursor
|
|
| 42 |
|
Vindesine |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
59917-39-4, 53643-48-4 |
40839
|
|
Synonyms:
3-(aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-(Aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-(Aminocarbonyl)-O(sup 4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-Carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-carbamoyl-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
53643-48-4
AC1L24KY
C43H55N5O7
CHEBI:36373
CHEMBL219146
CID40839
Compound 112531
D06304
DAVA
DB00309
Desacetylvinblastine amide
Desacetylvinblastine amide sulfate
Desacetylvinblastine Amide Sulfate
EG labo brand OF vindesine sulfate
EINECS 258-682-2
Eldesine
Eldisine
Enison
|
HMS2090E15
HSDB 6961
Lilly 112531
Lilly brand OF vindesine sulfate
LS-162145
methyl (5S,7S,9S)-9-[(2b,3b,4b,5a,12b,19a)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate
methyl (5S,7S,9S)-9-[(2beta,3beta,4beta,5alpha,12beta,19alpha)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate
MolPort-005-933-570
NSC-245467
STOCK1N-75293
Sulfate, vindesine
UNII-RSA8KO39WH
Vindesin
Vindesina
Vindesina [INN-Spanish]
vindesine
Vindesine (USAN/INN)
Vindesine [USAN:BAN:INN]
Vindesine [USAN:INN:BAN]
Vindesine sulfate
Vindesine Sulfate
Vindesinum
Vindesinum [INN-Latin]
|
|
| 43 |
|
Cladribine |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
4291-63-8 |
20279
|
|
Synonyms:
(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
(2R,3S,5R)-5-(6-amino-2-Chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
2 Chlorodeoxyadenosine
24757-90-2
2CdA
2-CdA
2-chloro-2'-Deoxyadenosine
2-Chloro-2'-deoxyadenosine
2-chloro-2'-Deoxy-b-adenosine
2-chloro-2'-Deoxy-beta-adenosine
2-Chloro-2'-deoxy-beta-adenosine
2-chloro-2'-Deoxy-β-adenosine
2-chloro-6-amino-9-(2-Deoxy-b-D-erythro-pentofuranosyl)purine
2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine
2-chloro-6-amino-9-(2-Deoxy-beta-D-erythro-pentofuranosyl)purine
2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine
2-chloro-6-amino-9-(2-Deoxy-β-D-erythro-pentofuranosyl)purine
2-chloro-deoxyadenosine
2-chloro-Deoxyadenosine
2-Chlorodeoxyadenosine
2ClAdo
2'-Deoxy-2-chloroadenosine
4291-63-8
AC1L2FXP
AC-7591
Adenosine, 2-chloro-2'-deoxy
BRN 0624220
C10H12ClN5O3.C3H8
CHEBI:567361
CHEMBL1619
Chlorodeoxyadenosine
CID20279
CL9
Cladarabine
Cladaribine
cladribina
Cladribina
cladribine
Cladribine
|
Cladribine (JAN/USAN/INN)
Cladribine [USAN:INN:BAN]
cladribinum
Cladribinum
CldAdo
CPD000058553
D01370
D017338
DB00242
FT-0080707
HMS2052K13
HSDB 7564
Leustat
Leustatin
Leustatin (TN)
Leustatin, 2-chlorodeoxyadenosine, Cladribine
Litak
LS-15109
MLS000028377
MLS000028484
MLS000759397
MLS001077345
MolPort-002-054-532
MolPort-005-935-074
Movectro
Mylinax
NCGC00022567-05
NCGC00164384-01
NSC 105014
NSC 105014-F
NSC-105014
RWJ 26251
RWJ-26251
RWJ-26251-000
S1199_Selleck
SAM001246526
SMR000058553
UNII-47M74X9YT5
ZINC03798064
|
|
| 44 |
|
Lenograstim |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
135968-09-1 |
|
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
|
|
| 45 |
|
Denileukin diftitox |
Approved, Investigational |
Phase 4,Phase 2,Phase 1,Not Applicable |
|
173146-27-5 |
|
|
Synonyms:
|
|
Interleukin-2/diptheria toxin fusion protein
|
|
| 46 |
|
Bexarotene |
Approved, Investigational |
Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 |
|
153559-49-0 |
82146
|
|
Synonyms:
153559-49-0
3-methyl-TTNEB
3-Methyl-ttneb
4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid
4-(1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid
4-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid
4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid
4-[1-3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthaleneyl)vinyl]benzene carboxylic acid
9RA
AC1L32UG
Bexaroten
Bexarotene
Bexarotène
Bexarotene (USAN/INN)
Bexarotene [USAN]
bexaroteno
Bexaroteno
bexarotenum
Bexarotenum
BIDD:PXR0021
C095105
CHEBI:50859
CHEMBL1023
CID82146
D03106
DB00307
Elan brand of bexarotene
|
Elan brand OF bexarotene
HMS2089L14
HSDB 7453
I14-1941
LG 1069
LG100069
LG-100069
LG1069
LG69 compound
LG69 Compound
LGD 1069
LGD1069
LGD-1069
Ligand brand of bexarotene
Ligand brand OF bexarotene
LS-38306
MolPort-003-845-030
NCGC00181016-01
P-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-Pentamethyl-2-naphthyl)vinyl)benzoate
p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
P-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-Pentamethyl-2-naphthyl)vinyl)benzoic acid
P-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
p-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl]benzoic acid
SBB067189
Targret
Targretin
Targretin (TN)
Targretin-gel
Targretyn
Targrexin
UNII-A61RXM4375
|
|
| 47 |
|
Vidarabine |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
24356-66-9 |
32326
21704
|
|
Synonyms:
(+)-Cyclaradine
.beta.-Adenosine
.beta.-D-Adenosine
1odi
2-(6-amino-PURIN-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
2-(6-AMINO-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
2946-52-3
2fqy
2gl0
30143-02-3
3080-29-3
3228-71-5
4005-33-8
46946-45-6
46969-16-8
524-69-6
5536-17-4
58-61-7
9 beta Arabinofuranosyladenine
9 beta D Arabinofuranosyladenine
9-Arabinosyladenine
9-b-D-Arabinofuranosyl-9H-purin-6-amine
9-b-D-Arabinofuranosyladenine
9-beta-Arabinofuranosyladenine
9-beta-D-Arabinofuranosyl-9H-purin-6-amine
9-beta-D-arabinofuranosyl-adenine
9-beta-D-Arabinofuranosyladenine
9-beta-D-Arabinofuranosyl-adenine
9-β-D-arabinofuranosyl-9H-purin-6-amine
9-β-D-arabinofuranosyladenine
A 9251
a, alpha-Ara
a, Ara
a, beta-Ara
A0152
A4036_SIGMA
A4676_SIGMA
A5762_SIGMA
A9251_SIGMA
AC1L18OL
AC1L1U8O
AC1L2IWM
AC1L2SCM
AC1O4WIN
AC1O8PY7
AC1Q1ID3
AC1Q4Y1Z
AC1Q52XU
Adenine arabinoside
Adenine nucleoside
Adenine riboside
Adenine xyloside
adenine-D-ribose
Adenocard
Adenocard (TN)
Adenocard, Adenosine
Adenocor
Adenoscan
Adenoscan (TN)
Adenosin
Adenosin [German]
adenosine
Adenosine (JAN/USP)
Adenosine [USAN:BAN]
Adenosine arabinose
ADENOSINE, U.S.P.
Adenosine-8-14C
Adensoine
Ade-Rib
ADN
AI3-52413
AI3-52821
alpha Ara a
alpha D Arabinofuranosyladenine
alpha-Ara a
alpha-Ara A
alpha-D-Arabinofuranosyladenine
Ambap5536-17-4
AR-1H6029
Ara a
Ara A
Ara-a
Ara-A
ARA-A NSC 247519
Araadenosine
Ara-ATP
Arabinofuranosyladenine
Arabinoside adenine
Arabinoside, adenine
Arabinosyl adenine
Arabinosyladenine
Arabinosyl-adenine
Arasena-A
Armes
Armes (TN)
BB_NC-0565
beta Ara a
beta-Adenosine
beta-Ara a
beta-Ara A
beta-D-Adenosine
Bio1_000437
Bio1_000926
Bio1_001415
bmse000061
Boniton
BPBio1_000898
BRN 0624881
BSPBio_000816
BSPBio_001796
BSPBio_002000
C00212
CAS-5536-17-4
Caswell No. 010B
CCRIS 2557
CCRIS 3383
CHEBI:136932
CHEBI:16335
CHEBI:45327
CHEMBL1090
CHEMBL20247
CHEMBL477
CI 673
CI-673
CID102198
CID191
CID21704
CID60961
CID6420052
CID6713976
CPD000471872
D000241
D00045
D06298
DB00640
DivK1c_000191
EINECS 200-389-9
EINECS 217-911-6
|
EINECS 226-893-9
EU-0100123
FT-0082881
HMS1570I18
HMS1920A13
HMS1921K05
HMS2090F06
HMS2091G13
HMS2092C16
HMS500J13
HSDB 6514
I01-1121
IDI1_000191
KBio1_000191
KBio2_002418
KBio2_004986
KBio2_007554
KBio3_001296
KBio3_001500
KBioGR_001224
KBioSS_002424
L000094
Lopac0_000123
LS-15059
LS-15085
MEDR-640
MLS000069638
MLS000699527
MLS001066352
MLS001333133
MLS001333134
MLS002153227
MLS002153992
MolPort-001-785-903
MolPort-001-838-229
MolPort-003-666-308
Monarch brand OF vidarabine
Myocol
NCGC00016656-01
NCGC00023673-03
NCGC00023673-04
NCGC00023673-05
NCGC00023673-06
NCGC00023673-07
NCGC00094579-01
NCGC00094579-02
NCGC00094579-03
NCGC00094579-04
NCGC00178869-01
NCGC00179417-01
nchembio.143-comp9
nchembio.186-comp109
nchembio.64-comp4
nchembio706-5
NCI60_003823
NCI60_037192
NCIOpen2_003303
NCIOpen2_005376
NINDS_000191
NSC 247519
NSC 404241
NSC 627048
NSC 7359
NSC 7652
NSC247519
NSC404241
NSC-404241
NSC627048
NSC70422
NSC7359
NSC7652
NSC80832
NSC87676
NSC91041
Nucleocardyl
Pallacor
Parke davis brand OF vidarabine
PDSP1_001036
PDSP2_001020
Polyadenosine
Polyriboadenosine
Prestwick_983
Prestwick0_000768
Prestwick1_000768
Prestwick2_000768
Prestwick3_000768
RAB
S1647_Selleck
S1784_Selleck
SAM002564191
Sandesin
SMP1_000312
SMR000058216
SMR000225041
SMR000471872
SMR001233326
SPBio_001194
SPBio_001491
SPBio_002755
Spectrum_001894
SPECTRUM1500107
SPECTRUM1500609
Spectrum2_001257
Spectrum2_001336
Spectrum3_000288
Spectrum3_000580
Spectrum4_000782
Spectrum5_001429
Spongoadenosine
SR 96225
SR-96225
STK361815
SUN-Y4001
TL8003749
UNII-3XQD2MEW34
UNII-K72T3FS567
USAF CB-10
V0098
Vidarabin
Vidarabina
Vidarabina [DCIT]
Vidarabine
Vidarabine (JAN)
Vidarabine anhydrous
Vidarabinum
Vira a
Vira ATM
Vira-a
ViraA
Vira-A
Vira-A, Vidarabine
VIRDARABINE
XA
Xylosyl A
Xylosyladenine
ZINC00970363
ZINC02169830
|
|
| 48 |
|
Sirolimus |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable |
|
53123-88-9 |
46835353
6436030
5284616
|
|
Synonyms:
(-)-rapamycin
(-)-Rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AC-722
Ambotz53123-88-9
Antibiotic AY 22989
AY 22989
AY22989
AY-22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
FT-0082351
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
|
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MolMap_000043
MolPort-003-959-433
MS-R001
NCGC00021305-05
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
Rapammune
Rapamune
Rapamune (TN)
rapamycin
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin from Streptomyces hygroscopicus
Rapamycin Immunosuppressant Drug
RPM
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
sirolimus
Sirolimus
sirolimús
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
sirolimusum
SMP1_000255
SMR000058564
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
Wy 090217
WY-090217
|
|
| 49 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
22916-47-8 |
4189
|
|
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
Aflorix(nitrate)
AKOS001574474
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
Brentan
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
Conofite(nitrate)
CPD-4501
D00416
Dactarin
Daktarin iv
Daktarin IV
DB01110
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Esteve brand OF miconazole
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
Lotrimin AF(nitrate)
LS-78378
MCZ
Micantin (nitrate)
Miconasil nitrate
Miconasil Nitrate
Miconazol
|
Miconazol [INN-Spanish]
miconazole
Miconazole
Miconazole (JP15/USP/INN)
Miconazole [USAN:BAN:INN:JAN]
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MJR 1762
MLS002222203
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (tn)
Monistat iv (TN)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
Nitrate, miconasil
Nitrate, miconazole
Novo-Miconazole Vaginal Ovules
NSC 170986
NSC169434
NSC170986
Oprea1_091955
Prestwick_335
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
Spectrum_000965
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
STK834405
STOCK1S-93556
UNII-7NNO0D7S5M
Vusion
Zimycan
|
|
| 50 |
|
Everolimus |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable |
|
159351-69-6 |
6442177
|
|
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
001, RAD
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
40-O-(2-Hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
Certican
CERTICAN(R)
CHEMBL1201755
D02714
DB01590
everolimus
|
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD, SDZ
RAD001
RAD-001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
RAD-001C
S1120_Selleck
SDZ RAD
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
|
|
Interventional clinical trials:
(show top 50)
(show all 6814)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma |
Unknown status |
NCT02585947
|
Phase 4 |
Tenofovir |
| 2 |
Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma |
Unknown status |
NCT01088750
|
Phase 4 |
cyclophosphamide;prednisolone;vinblastine sulfate |
| 3 |
PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia |
Unknown status |
NCT02996617
|
Phase 4 |
rhG-CSF regimen;Pegylated rhG-CSF regimen |
| 4 |
PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation |
Unknown status |
NCT02905942
|
Phase 4 |
PEG-rhG-CSF;rhG-CSF |
| 5 |
Treatment of Diffuse Large B Cell Lymphoma |
Unknown status |
NCT01949818
|
Phase 4 |
Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen |
| 6 |
Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation |
Unknown status |
NCT03010579
|
Phase 4 |
erythropoietin;iron supplementation |
| 7 |
Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults |
Unknown status |
NCT00797810
|
Phase 4 |
Rituximab |
| 8 |
Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma |
Unknown status |
NCT01765231
|
Phase 4 |
Entecavir prophylaxis;Observation arm |
| 9 |
Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy |
Unknown status |
NCT01768195
|
Phase 4 |
Entecavir prophylaxis |
| 10 |
Low Grade Lymphoma |
Unknown status |
NCT01698866
|
Phase 4 |
|
| 11 |
CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL |
Unknown status |
NCT02533700
|
Phase 4 |
CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles |
| 12 |
Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET |
Unknown status |
NCT00188149
|
Phase 4 |
Combined chemotherapy (ABVD, BACOPP-D) |
| 13 |
Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors |
Unknown status |
NCT02929615
|
Phase 4 |
|
| 14 |
Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) |
Unknown status |
NCT02347878
|
Phase 4 |
Aprepitant |
| 15 |
Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice |
Unknown status |
NCT01273441
|
Phase 4 |
PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin |
| 16 |
The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy |
Unknown status |
NCT02905916
|
Phase 4 |
PEG-rhG-CSF |
| 17 |
A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation |
Unknown status |
NCT02576327
|
Phase 4 |
Tropisetron;Dexamethasone;Aprepitant |
| 18 |
Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study |
Unknown status |
NCT02894645
|
Phase 4 |
Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib |
| 19 |
Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients |
Unknown status |
NCT02690922
|
Phase 4 |
Dasatinib;prednisone;dexamethasone;methotrexate |
| 20 |
HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL |
Unknown status |
NCT01873807
|
Phase 4 |
IDA;CTX;VP-16 |
| 21 |
Treatment of High Risk Adult Acute Lymphoblastic Leukemia |
Unknown status |
NCT00853008
|
Phase 4 |
Vincristine;Daunorubicin;Prednisone;Mitoxantrone;Cytosine Arabinoside;Dexamethasone;Methotrexate (MTX);Cytarabine;ASP;Mercaptopurine;Teniposide;Hydrocortisone |
| 22 |
The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia |
Unknown status |
NCT00846703
|
Phase 4 |
6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone |
| 23 |
Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 |
Unknown status |
NCT00222612
|
Phase 4 |
Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance |
| 24 |
Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses |
Unknown status |
NCT00192673
|
Phase 4 |
PEG-asparaginase |
| 25 |
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) |
Unknown status |
NCT00198991
|
Phase 4 |
Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine |
| 26 |
German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia |
Unknown status |
NCT00198978
|
Phase 4 |
Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase |
| 27 |
Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia |
Unknown status |
NCT01990807
|
Phase 4 |
Idarubicin(IDA) |
| 28 |
Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer |
Unknown status |
NCT00274885
|
Phase 4 |
oxaliplatin |
| 29 |
Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma |
Completed |
NCT00168727
|
Phase 4 |
ibritumomab tiuxetan (Zevalin®) |
| 30 |
Treatment of Peripheral T-cell Lymphoma |
Completed |
NCT01664975
|
Phase 4 |
GDPT regimen;CHOP regimen |
| 31 |
PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy |
Completed |
NCT02805218
|
Phase 4 |
PEG-rhG-CSF |
| 32 |
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. |
Completed |
NCT00430352
|
Phase 4 |
rituximab [MabThera/Rituxan] |
| 33 |
Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) |
Completed |
NCT00211198
|
Phase 4 |
ONTAK (denileukin difitox, DAB389IL-2) |
| 34 |
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) |
Completed |
NCT01007448
|
Phase 4 |
bexarotene;bexarotene |
| 35 |
Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma |
Completed |
NCT00969462
|
Phase 4 |
Doxorubicin |
| 36 |
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms |
Completed |
NCT01164475
|
Phase 4 |
Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor |
| 37 |
German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults |
Completed |
NCT00199017
|
Phase 4 |
Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine |
| 38 |
Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma |
Completed |
NCT01124526
|
Phase 4 |
Rituximab Fludarabine Cyclophosphamide |
| 39 |
Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) |
Completed |
NCT00153530
|
Phase 4 |
methotrexate |
| 40 |
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma |
Completed |
NCT01180049
|
Phase 4 |
temsirolimus;temsirolimus |
| 41 |
Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B |
Completed |
NCT00926757
|
Phase 4 |
Entecavir prophylaxis;Therapeutic entecavir |
| 42 |
Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma |
Completed |
NCT01569724
|
Phase 4 |
|
| 43 |
An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) |
Completed |
NCT02782845
|
Phase 4 |
Chemotherapy;Immunochemotherapy;Pegfilgrastim |
| 44 |
LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) |
Completed |
NCT00466258
|
Phase 4 |
R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment |
| 45 |
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients |
Completed |
NCT00050999
|
Phase 4 |
ONTAK |
| 46 |
Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients |
Completed |
NCT00051012
|
Phase 4 |
ONTAK |
| 47 |
Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma |
Completed |
NCT00090038
|
Phase 4 |
rituximab |
| 48 |
Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy |
Completed |
NCT00230217
|
Phase 4 |
Rasburicase (SR29142) |
| 49 |
Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults |
Completed |
NCT00199082
|
Phase 4 |
Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine |
| 50 |
Prevention of CHOP-induced Chronic Cardiotoxicity |
Completed |
NCT00162955
|
Phase 4 |
Valsartan |
Inferred drug relations via
UMLS
73
/
NDF-RT
51
:
|
